

ShareHope

SHAREHOPE MEDICINE CO., LTD.

Stock Code: 8403

115

Annual Shareholders' Meeting Handbook



-  Stock Code: 8403
-  Meeting Time: 9:00 AM, June 23, 2026
-  Venue: 5F., No. 107, Minsheng Rd.,
Taoyuan Dist., Taoyuan City
-  Meeting Format: In-Person
Shareholders' Meeting



Missioncare / Since 1975
Missioncare Healthcare
Asia's Leading Healthcare Ecosystem



50+
Years of Heritage



18
Cities &
Counties Served



1,233
Service Locations
Nationwide



敬盛綜合醫院
Min-Sheng General Hospital

HVD

哈佛健診



躍動連鎖藥局

PHI

精準健康

智醫康寓

HEALTHY RESIDENCE



敬成

TECHGROUP

方廣建設股份有限公司

Table of Contents

I. Meeting Procedure	2
II. Meeting Agenda	3
Agenda1: Report Matters	4
Agenda2: Recognition Matters	5
Agenda3: Discussion Matters	7
Agenda4: Extemporaneous Motions	10
Agenda5: End of discussion	10
III. Attachments	11
1. 2025 Annual Business Report	11
2. 2025 Annual Audit Committee Review Report	13
3. 2025 Accountants Audit Report, Financial Statements and Consolidated Financial Statements	14
III. Appendix	32
1. Articles of Incorporation	32
2. Rules of Procedure for Shareholders' Meeting	37
3. Shareholding of Directors	49

ShareHope Medicine Co., Ltd.
Procedure for the 2026 Annual Meeting of Shareholders

- 1、 Commencement of the Meeting**
- 2、 Chairperson's Statements**
- 3、 Report Matters**
- 4、 Recognition Matters**
- 5、 Discussion Matters**
- 6、 Extemporaneous Matters**
- 7、 Adjournment**

ShareHope Medicine Co., Ltd.
2026 Annual General Shareholders Meeting Agenda

Time/Date: 9:00 a.m., June 23, 2026(Tuesday)

Place: 5F., No. 107, Minsheng Rd., Taoyuan Dist., Taoyuan City

1. Commencement of the Meeting

2. Chairperson's Statements

3. Report Matters

- (1) 2025 Business Report.
- (2) 2025 Audit Committee Review Report.
- (3) 2025 Distributable Compensation for Directors and Employees.
- (4) Report on the simplified consolidation of the Company's subsidiary, Medzoneasia Co., Ltd.

4. Recognition Matters

- (1) Adoption of the 2025 Business Report, Financial Statement and Combined Financial Statement.
- (2) Distribution of 2025 Profits.

5. Discussion Matters:

- (1) Amendment to the Company's "Rules of Procedure for Shareholders' Meetings".

6. Extemporaneous Matters

7. Adjournment

Report Matters

Report No. 1

Proposal: 2025 Business Reports

Explanation: The 2025 Business Report is attached as pp.10.

Report No. 2

Proposal: 2025 Audit Committee Review Report

Explanation: The 2025 Business Report is attached as pp.12.

Report No. 3

Proposal: 2025 Distributable Compensation for Directors and Employees.

Explanation:

1. Article 21 of the Company's Articles of Association stipulates the following principles for the allocation of director remuneration and employee remuneration: If the Company has a profit in a given year, 6% to 10% shall be allocated to employee remuneration (no less than 10% of the employee remuneration shall be allocated to lower-level employees). This shall be distributed in the form of shares or cash, as decided by the Board of Directors, and the recipients shall include employees of subsidiary companies who meet certain conditions. The Company may allocate no more than 3% of the aforementioned profit amount to director remuneration, as decided by the Board of Directors.
2. The Company's pre-tax net profit for fiscal year 2025, excluding director remuneration and employee remuneration, was NT\$188,994,118, which meets the profit requirement stipulated in the Articles of Association. Therefore, it is proposed to allocate 1% of the aforementioned pre-tax net profit to director remuneration and 6% to employee remuneration, in accordance with the Articles of Association, with allocations of NT\$1,889,941 and NT\$11,339,647 respectively.

Report No. 4

Proposal: Report on the simplified consolidation of the Company's subsidiary, Medzoneasia Co., Ltd.

Explanation:

1. To simplify organization, reorganize resources, and increase management efficiency, our company has completed a simplified merger with our 92% owned subsidiary, Medzoneasia Co., Ltd., in accordance with Article 19 of the Enterprise Mergers and Acquisitions Act and other relevant regulations. The merger base date is January 1, 2025 (Republic of China year 114). From the merger base date, all assets, liabilities, and rights and obligations of Medzoneasia Co., Ltd. (i.e., the dissolved company) shall be assumed by our company (i.e., the surviving company).
2. In accordance with Article 26 of the Enterprise Mergers and Acquisitions Act, the surviving company may report on the merger matters at the first shareholders' meeting after the merger.

Recognition Matters

Report No. 1 (Board of Directors Proposal)

Proposal: Adoption of the 2025 Business Report, Financial Statement and Combined Financial Statement.

Explanation:

1. The Company's Financial Statements, including the balance sheet, income statement, statement of changes in shareholders' equity, and statement of cash flows, were audited by independent auditors, KPMG. Also Business Report and Financial Statements have been approved by the Board and examined by the The Audit Committee.
2. The 2025 Business Report, independent auditors' audit report, and the above-mentioned Financial Statements are attached in the Meeting Agenda, pp. 11-31.

3. Please approve.

Resolution:

Report No. 2 (Board of Directors Proposal)

Proposal: Distribution of 2025 Profits.

Explanation: 1. The company's 2025 surplus distribution plan was approved by the resolution of the 13th meeting of the eighth session of the board of directors on May 8, 2026. The surplus distribution table is as follows:

ShareHope Medicine Co., Ltd.
Distribution of 2025 Profits



Unit: NTD

Item	Amount
Unappropriated retained earnings of prior years	668,815,916
2025 net profit	141,726,443
Share of other comprehensive profit or loss of subsidiaries recognized using the equity method	550,340
Determine the change in the remeasurement of the benefit plan for this period	(296,180)
The net profit after tax of the current period is added to the net profit of the current period, and the items other than the net profit after tax of the current period are included in the current year's undistributed surplus	141,980,603
Provision of statutory surplus reserve (10%)	(14,198,060)
Special surplus reserve shall be set aside in accordance with the law.	(143,306,493)
Deficit yet to be compensated – at the end of 2025	653,291,966
Items for compensating deficit:	
Shareholder cash dividends - 0.60000000 NTD per share	(82,584,206)
Undistributed surplus at the end of the period	570,707,760
Note: Priority distribution of 2025 annual net profit	

Chairperson:
Hung-jen Yang



Manager:
Ching-wen Liu



Chief Accounting Officer:
Ya-mei Huang



2. If there is a change in the company's share capital that affects the number of shares in circulation and the shareholder's allotment dividend rate changes and needs to be revised, it is proposed to submit to the shareholders' meeting to authorize the chairman to handle it with full authority; the cash dividend distribution is less than 1 NTD. The amount is included in other income of the company.
3. After this case is approved by the resolution of the shareholders' general meeting, the board of directors will hold a separate meeting to decide on the ex-rights and interest base date and other related matters.
4. Please approve.

Resolution:

Discussion Matters

Proposal 1: (Proposed by the Board)

Proposal: Amendment to the "Rules of Procedure for Shareholders' Meetings" for Discussion.

Explanation: 1. In accordance with Articles 3 and 13 of the "Referential Example of the Rules of Procedure for Shareholders' Meetings of ○○ Corporation" amended by the Financial Supervisory Commission (FSC) in its letter dated February 13, 2026 (FSC Letter No. 1150331020), this company proposes to amend its "Rules of Procedure for Shareholders' Meetings."

2. The proposed amendments to Articles 3, 13, and 24 of this company's Rules of Procedure for Shareholders' Meetings are summarized in the table below:

Amendments	Current Provisions	Explanation
<p>Article 3</p> <p>(Items 1 to 3 omitted) The Company shall, thirty days prior to the annual general meeting or fifteen days prior to the extraordinary general meeting, prepare electronic files of the following documents and transmit them to the public information observation station: the notice of the shareholders' meeting, proxy forms, relevant approval motions, discussion motions, the reasons and explanations for all motions regarding the election or removal of directors and supervisors, the shareholders' meeting procedural manual, and supplementary meeting materials. The Company shall, fifteen days prior to the shareholders' meeting, prepare the shareholders' meeting procedural manual and supplementary meeting materials for shareholders to access at any time and display them at the Company and its appointed professional stock brokerage agencies.</p> <p>(The following omitted)</p>	<p>Article 3</p> <p>(Items 1 to 3 omitted) The Company shall, 30 days prior to the Annual General Meeting or 15 days prior to the Extraordinary General Meeting, prepare electronic files of the notice of the shareholders' meeting, proxy forms, relevant approval documents, discussion documents, and explanatory materials for all proposals, including the election or removal of directors and supervisors, and transmit them to the Public Information Observation Station. Furthermore, 21 days prior to the Annual General Meeting or 15 days prior to the Extraordinary General Meeting, the Company shall prepare electronic files of the shareholders' meeting proceedings and supplementary meeting materials and transmit them to the Public Information Observation Station. However, if the Company's paid-in capital as of the end of the most recent fiscal year exceeds NT\$10 billion, or if the combined shareholding ratio of foreign and mainland Chinese investors recorded in the shareholder register at the most recent fiscal year's Annual General Meeting exceeds 30%, the Company shall complete the transmission of the aforementioned electronic files 30 days prior to the Annual General Meeting. 15 days prior to the shareholders' meeting, the Company shall prepare the shareholders' meeting proceedings and supplementary meeting materials for shareholders to access at any time and display them at the Company and its appointed professional stock brokerage agency.</p> <p>(The following omitted)</p>	<p>In line with the amendment to Article 6, Paragraph 4 of the "Regulations Governing the Recording and Compliance of the Shareholders' Meeting Procedure Manual for Publicly Listed Companies", the scope of application of the requirement to disclose the procedure manual and related information 30 days before the shareholders' meeting has been expanded to all listed and over-the-counter companies.</p>
<p>Article 13</p> <p>(Items 1 through 6 omitted) The scrutineers and vote counters for voting on resolutions shall be appointed by the Chairman, but the scrutineers must be shareholders.</p> <p>In the event of a shareholders' meeting with a resolution to elect directors where the number of candidates exceeds the number of seats to be elected, a resolution to remove a director, or a resolution stipulated in Articles 185 and 316 of the Company Act, Articles 18, 27, 29, and 35 of the Enterprise Mergers and Acquisitions Act, or Articles 24, Paragraph 2, Subparagraph 1, and 26, Paragraph 2, Subparagraph 1 of the Financial Holding Company Act, the Chairman shall appoint a lawyer, accountant, or notary public as scrutineers.</p>	<p>Article Thirteen</p> <p>(Items 1 through 6 omitted) The vote counters and supervisors for the voting on the resolutions shall be appointed by the Chairman, but the vote counters shall be shareholders.</p> <p>(The following omitted)</p>	<p>I. When a shareholders' meeting proposes the election of directors and the number of candidates exceeds the number of seats to be elected, proposes the removal of directors, or proposes any of the motions stipulated in Articles 185 and 316 of the Companies Act, Articles 18, 27, 29, and 35 of the Mergers and Acquisitions Act, or Articles 24(2)(1) and 26(2)(1) of the Financial Holding Companies Act, the</p>

Amendments	Current Provisions	Explanation
<p>The person appointed by the Chairman pursuant to the preceding paragraph may not be responsible for matters related to the voting procedure, nor may they be a director, manager, or employee of the company or its related enterprises.</p> <p>The scrutineers shall supervise the voting and vote counting process and sign the election results tally sheet.</p> <p>If scrutineers are appointed pursuant to Item 8, the minutes of the shareholders' meeting shall state the name and title of the scrutineers.</p> <p>(The following items are moved to the next item in order)</p>		<p>chairman should appoint a lawyer, accountant, or notary public as scrutineers.</p> <p>II. Referring to the Malaysian Listing Rules, a ninth provision is added, stipulating that scrutineers appointed by the chairman under Article 8 should not only possess professional qualifications but also independence to avoid disputes. Regarding the determination of independence, scrutineers may not participate in matters related to the voting process of the shareholders' meeting, nor may they be directors, managers, or employees of the company or its related enterprises.</p> <p>III. Clarifying that the responsibilities of general scrutineers and independent scrutineers are to supervise the voting and counting process at the shareholders' meeting and sign the election results tally sheet to indicate accountability, a tenth provision is added. Fourth, in accordance with the listing rules of Singapore and Hong Kong, the names of scrutineers should be included in the minutes of shareholders' meetings to enhance transparency. Therefore, an eleventh item is added, requiring that the name and title of the</p>

Amendments	Current Provisions	Explanation
		independent scrutineer in Item 8 be included in the minutes.
<p>Article 24. These Regulations were adopted on June 25, 2008 (Republic of China Year 97). First Revision: November 1, 2008 (Republic of China Year 97). Second Revision: June 29, 2012 (Republic of China Year 101). Third Revision: June 20, 2013 (Republic of China Year 102). Fourth Revision: June 23, 2015 (Republic of China Year 104). Fifth Revision: June 27, 2018 (Republic of China Year 107). Sixth Revision: June 30, 2020 (Republic of China Year 109). Seventh Revision: July 30, 2021 (Republic of China Year 110). Eighth Revision: June 29, 2022 (Republic of China Year 111). Ninth Revision: June 30, 2023 (Republic of China Year 112). Tenth Revision: June 23, 2026 (Republic of China Year 115).</p>	<p>Article 24. These Regulations were adopted on June 25, 2008 (Republic of China Year 97). First Revision: November 1, 2008 (Republic of China Year 97). Second Revision: June 29, 2012 (Republic of China Year 101). Third Revision: June 20, 2013 (Republic of China Year 102). Fourth Revision: June 23, 2015 (Republic of China Year 104). Fifth Revision: June 27, 2018 (Republic of China Year 107). Sixth Revision: June 30, 2020 (Republic of China Year 209). Seventh Revision: July 30, 2021 (Republic of China Year 110). Eighth Revision: June 29, 2022 (Republic of China Year 111). Ninth Revision: June 30, 2023 (Republic of China Year 112).</p>	<p>Added revision date.</p>

3.Please discuss.

Resolution:

Extemporary Matters

Adjournment

Attachment 1: 2025 Business Report

ShareHope Medicine Co., Ltd.

2025 Business Report



Ladies and gentlemen, shareholders:

Our consolidated revenue for fiscal year 2025 was NT\$4,357,867,000, with a net profit after tax of NT\$141,727,000 and earnings per share of NT\$1.03. Revenue increased compared to the previous year, and profit, excluding the gains from the disposal of real estate transactions in fiscal year 2024, also increased compared to the previous year.

Looking at the company's development based on the 2025 operating results, businesses with insufficient synergy have been gradually consolidated and improved. The operating performance of all subsidiaries and investments has been steadily improving and is continuing to strengthen. The subsidiary, Mytrex Health Technologies, Inc. (YES Health Co., Ltd.), is expected to achieve a breakthrough this year, and the company will fully support it.

A summary of the operating results is as follows:

➤ Consolidated Financial Statements

(Unit: thousand)

	2025	2024
operating income	4,357,867	4,325,831
Operating cost	3,648,854	3,611,427
operating profit	709,013	714,404
Operating expenses	628,199	750,297
Other gains and expenses, net	90,041	214,382
business interest	170,855	178,489
Non-operating income and expenses	(20,705)	(4,579)
Net profit before tax	150,150	173,910
Income tax expense	38,253	51,512
Net profit for the period	111,897	122,398
Net profit for the period is attributable to:		
parent company owner	141,727	200,097
non-controlling interest	(29,830)	(77,699)

➤ Individual Financial Statement Summary

	2025	2024
Net profit for the year (thousand NTD)	141,727	200,097
Earnings per share: basic (NTD)	1.03	1.45
Earnings per share: diluted (NTD)	1.03	1.45

(Note) 2023 is retrospectively adjusted earnings per share.

Chairperson:
Hung-jen Yang



Manager:
Ching-wen Liu



Chief Accounting Officer:
Ya-mei Huang



Audit Committee Review Report

The company's 2025 annual business report, financial statements and consolidated financial statements, and profit distribution proposals, etc., among which the financial statements and consolidated financial statements have been checked by KPMG, and the audit report has been issued. The above-mentioned business report, financial statement, consolidated financial statement and profit distribution case have been reviewed and completed by the Audit Committee according to the law, and there are no discrepancies, and they are prepared in accordance with the provisions of Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act. Please review the report.

Sincerely,
ShareHope Medicine Co., Ltd.
2026 Annual General Meeting of Shareholders

ShareHope Medicine Co., Ltd.

The Audit Committee

Convener: Wu Genzai



May/8, 2026

Attachment 3: 2025 Accountants Audit Report, Financial Statements and Consolidated Financial Statements.

Independent Auditors' Report

Submitted to the Board of Directors of ShareHope Medicine Co., Ltd. and subsidiaries for review

Audit opinion

We have audited the Consolidated Balance Sheet of ShareHope Medicine Co., Ltd. and its subsidiaries (ShareHope Group) on December 31, 2025 and 2024, and the Consolidated Statement of Comprehensive Income, Consolidated Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to Consolidated Financial Report (including the Summary of Major Accounting Policies) from January 1 to December 31, 2025 and 2024.

In our opinion, the Consolidated Financial Report referred to above has been prepared, in all material respects, in accordance with the Regulations Governing the Preparation of Financial Statements by Securities Issuers, International Financial Reporting Standards, International Accounting Standard, and their interpretations and interpretation announcements recognized by the Financial Supervisory Commission, and is adequate in expressing the consolidated financial position of the Group on December 31, 2025 and 2024, as well as its consolidated financial performance and consolidated cash flows from January 1 to December 31, 2025 and 2024.

Foundation of the Audit Opinion

The independent auditor performed the audit in compliance with the rules governing the certification of financial statements by entrusted independent auditors and the auditing standards. His responsibilities specified in these standards will be further explained in the section about independent auditors' responsibilities in auditing the Consolidated Financial Statements. The personnel subject to independence standards in the accounting firm, to which the said independent auditor is affiliated, have maintained independent from ShareHope Group in accordance with the CPA Professional and Ethical Guidelines, and have fulfilled other obligations under the Guidelines. We believe that we have obtained sufficient and appropriate audit evidence as the basis for expressing our audit opinion.

Key Audit Matters

A key audit matter is one that, in our professional judgment, is material to the audit of the Consolidated Financial Report of ShareHope Group for 2025. Given that such items have been considered in the course of auditing the Consolidated Financial Statements and forming the audit opinions, the independent auditor does not give opinions on these items separately. Based on the independent auditor's judgment, the key audit items that shall be included in the audit report are as follows:

Revenue recognition

For the accounting policy for revenue recognition and related disclosure information, please refer to Note 4(15), Note 6(26), and Note 7(2) of the Consolidated Financial Report.

Explanation on key audit items:

The operating revenue of ShareHope Group is a matter of concern to users of the financial statements and the competent authorities, and the Group's main sales customers are related parties of its medical system, whose operating revenue has a significant impact on the Consolidated Financial Statements. Accordingly, revenue recognition is among the important items to be evaluated by the independent auditor in the audit of the Consolidated Financial Statements of ShareHope Group.

Corresponding audit procedures:

The main audit procedures adopted by the independent auditor for the key audit items mentioned above include:

- Based on the understanding of the sales-related internal control procedures of ShareHope Group, establish internal control audit procedures in response to the risks generated thereof, to identify and evaluate the effectiveness of the internal control over sales transactions made by the Group with its related parties.
- Obtain sales revenue details from the management, confirm the completeness of the details, select adequate samples from the revenue details of main sales transactions with related parties, and review relevant vouchers and verify the delivery of goods and receipt of payments, so as to confirm whether the revenues are recognized after relevant obligations are fulfilled as well as the authenticity of revenue recognition.
- Inspect whether there are major discounts or returns of sales revenue subsequent to the sales transactions and evaluate the authenticity of the sales revenue.
- Send a letter of inquiry to relevant parties and confirm whether the recorded revenue is consistent with the transaction amount or has been adjusted appropriately.

Other Matters

ShareHope Medicine Co., Ltd. has prepared the Parent Company Only Financial Report for 2025 and 2024, and we have issued unqualified opinions respectively for reference.

Responsibilities of the Management and Governance Unit for the Consolidated Financial Report

The responsibility of the management is to prepare fairly presented Consolidated Financial Statements in accordance with the Regulations Governing the Preparation of Financial Statements by Securities Issuers, and the International Financial Reporting Standards, International Accounting Standard, and their interpretations and interpretation announcements recognized and issued by the Financial Supervisory Commission, and to maintain necessary internal control over the preparation of the Consolidated Financial Statements, so as to ensure no occurrence of material false statements due to fraud or error in the Consolidated Financial Statements.

The responsibility of the management in the preparation of the Consolidated Financial Statements also includes the evaluation of ShareHope Group's ability to continue business, the disclosure of related items, and the adoption of the accounting basis for continuation of the business, unless the management intends to liquidate ShareHope Group or close business, or there is no practical alternative to liquidation or close of the business.

The governing body (including the Audit Committee) of ShareHope Group is responsible for supervising the financial reporting process.

Our Responsibilities for Auditing the Consolidated Financial Report

The purpose of the independent auditor's audit of the Consolidated Financial Statements is to obtain reasonable assurance as to whether there are material false statements due to fraud or error in the Consolidated Financial Statements, and to issue an audit report. Reasonable assurance refers to the high degree of certainty. Nevertheless, there is no guarantee that the material false statements in the Consolidated Financial Statements will necessarily be detected merely based on the audit work conducted in compliance with the auditing standards. False statements may result from frauds or errors. False statements of several amounts or total amounts are considered material if they can reasonably be expected to affect the economic decisions made by users of the Consolidated Financial Statements.

The independent auditor performs professional judgment and professional skepticism when conducting an audit in accordance with the auditing standards. The independent auditor also undertakes the following tasks:


1. Identify and evaluate the risk of material false statements due to frauds or errors in the Consolidated Financial Statements, formulate and implement appropriate countermeasures for the risk evaluated, and obtain sufficient and appropriate audit evidence as the basis for audit opinions. Since fraud may involve collusion, forgery, intentional omission, false statements, or overstepping internal control, the risk of the failure to detect material false statements due to frauds is higher than that due to errors.
2. Obtain necessary understanding of the internal control essential to the audit, so as to formulate the appropriate audit procedures for the current situation, for all that the purpose is not to give opinions on the effectiveness of the internal control of ShareHope Group.
3. Evaluate the appropriateness of the accounting policies adopted by the management, as well as the reasonability of the accounting estimates and related disclosures made by them.
4. Draw conclusions on the appropriateness of the management's adoption of the accounting basis for continuation of the business, as well as whether there are significant uncertainties in events or situations that may give rise to material doubts about ShareHope Group's ability to continue its business, based on the audit evidences obtained. If the independent auditor believes that there are significant uncertainties in such events or situations, he shall remind users of the Consolidated Financial Statements to pay attention to the disclosures about the Consolidated Financial Statements, or revise the audit opinions when such disclosures are inappropriate. The independent auditor's conclusions are based on the audit evidences obtained up to the date of the audit report. However, future events or situations may result in ShareHope Group's loss of the ability to continue the business.
5. Evaluate the overall statements, structure, and contents of the Consolidated Financial Statements (including relevant notes), and whether relevant transactions and events are fairly presented in the Consolidated Financial Statements.
6. Obtain sufficient and appropriate audit evidence for the financial information of the constituent entities of the Group to give opinions on the Consolidated Financial Statements. The independent auditor is responsible for guiding, supervising, and executing the audit work of the Group, and for issuing audit opinions on the Group.

The items on which the independent auditor has communicated with the governing body include the planned scope and time of the audit work, as well as major audit findings (including significant deficiencies in internal control identified in the course of the audit).

The independent auditor has also provided the governing body with the statement that the personnel subject to independence standards in the accounting firm, to which the independent auditor is affiliated, have complied with the CPA professional and ethical guidelines regarding independence, and has communicated with the governing body on all relationships and other items that may be considered to affect the independence of independent auditors (including relevant protective measures).

We have decided on the key matters to be audited in the Consolidated Financial Report of the Group for 2025 based on the matters we communicated with the governance unit. The independent auditor has stated such items in the Independent Auditors' Report, unless some specific items are prohibited from disclosure according to laws and regulations, or the independent auditor decides not to communicate some items in the Independent Auditors' Report under extremely rare circumstances where it can be reasonably expected that the negative impact of such communication will outweigh the public interest it brings.


KPMG Taiwan



Astor Kou



CPAs:



Sinney Kuo



Number of documents : Tai-Tsai-Zheng-(6)-Zi-0930106739
approved and certified by the securities regulatory
March 13, 2026 Jin-Kuan-Zheng-Shen-Zi-1040003949

ShareHope Medicine Co., Ltd. and its subsidiaries

Consolidated Balance Sheet
December 31, 2025 and 2024

Unit: NTS thousand

	2025.12.31		2024.12.31			2025.12.31		2024.12.31	
	Amount	%	Amount	%		Amount	%	Amount	%
Assets					Liabilities and equity				
Current assets:					Current liabilities:				
1100 Cash and cash equivalents (Note 6(1))	\$ 1,338,686	20	1,459,635	20	2100 Short-term borrowings (Note 6(16) and 8)	\$ 431,371	7	433,087	6
1110 Financial assets at fair value through profit or loss - current (Note 6(2))	12,780	-	10,610	-	2110 Short-term bills payable (Note 6(17))	-	-	54,815	1
1120 Financial assets at fair value through other comprehensive income - non-current (Note 8)	87,264	1	-	-	2130 Contract liabilities - current (Note 6(26))	17,255	-	48,815	1
1136 Financial assets at amortized cost - current (Note 8)	139,001	2	23,010	-	2150 Notes payable	6,874	-	19,676	-
1150 Notes receivable (Note 6(4) and (26))	7,183	-	11,320	-	2170 Accounts payable	681,181	10	664,386	9
1170 Net accounts receivable (Note 6(4), (6) and (26))	233,804	4	258,074	4	2181 Accounts payable - related parties (Note 7)	563	-	1,020	-
1180 Net accounts receivable - related parties (Note 6(4), (6) and (26), and Note 7)	931,331	14	971,225	14	2200 Other payables (Note 6(21))	199,008	3	251,605	4
1200 Other net accounts receivable (Note 6(5))	27,600	1	50,829	1	2220 Other accounts payable - related parties (Note 7)	931	-	26,746	-
1210 Other accounts receivable - related parties (Note 6(5) and Note 7)	22,873	-	268,252	4	2230 Income tax liabilities for the period	18,976	-	24,433	-
1220 Income tax assets for the period	1,561	-	337	-	2280 Lease liabilities - current (Note 6(19))	95,306	2	109,778	2
130X Inventories (Note 6(7))	291,857	4	292,256	4	2322 Long-term borrowings due within one year (Note 6(18) and 8)	79,991	1	185,158	2
1410 Prepayments (Note 7)	35,810	1	36,916	1	2399 Other current liabilities	32,222	1	40,480	1
1470 Other current assets	2,441	-	9,928	-	Total current liabilities	<u>1,563,678</u>	<u>24</u>	<u>1,859,999</u>	<u>26</u>
Total current assets	<u>3,132,191</u>	<u>47</u>	<u>3,392,392</u>	<u>48</u>	Non-current liabilities:				
Non-current assets:					2540 Long-term borrowings (Note 6(18) and 8)	811,676	12	825,235	12
1510 Financial assets at fair value through profit or loss - non-current (Note 6(2))	24,210	-	27,853	-	2570 Deferred income tax liabilities (Note 6(23))	11,543	-	29,198	1
1517 Financial assets at fair value through other comprehensive income - non-current (Note 6(3))	430,675	7	770,686	11	2580 Lease liabilities - non-current (Note 6(19))	373,454	6	379,196	5
1536 Financial assets at amortized cost - non-current (Note 8)	43,533	1	43,334	1	2640 Net defined benefit liabilities - non-current	7,868	-	7,267	-
1550 Equity method investments (Note 6(9))	97,190	1	76,056	1	2645 Deposits received (Note 7)	14,948	-	19,756	-
1600 Property, plant and equipment (Note 6(11) and 8)	1,449,014	22	1,490,229	21	Total non-current liabilities	<u>1,219,489</u>	<u>18</u>	<u>1,260,652</u>	<u>18</u>
1755 Right-of-use assets (Note 6(12))	277,089	4	350,060	5	Total liabilities	<u>2,783,167</u>	<u>42</u>	<u>3,120,651</u>	<u>44</u>
1760 Investment property (Note 6(13) and 8)	171,089	3	111,884	2	Equity (Notes 6(8), (10) and (24)):				
1780 Intangible assets (Note 6(14))	310,072	5	322,120	4	3110 Ordinary share capital	1,376,404	21	1,310,861	18
1840 Deferred income tax assets (Note 6(23))	48,702	1	14,444	-	3200 Additional paid-in capital	1,150,776	17	1,150,037	16
194D Net long-term finance lease receivables (Note 6(6) and (26), and Note 7)	4,146	-	15,969	-	3310 Legal reserves	249,091	4	229,009	3
1990 Other non-current assets (Note 6(15) and 7)	627,530	9	486,690	7	3350 Undistributed earnings	810,797	12	819,984	12
Total non-current assets	<u>3,483,250</u>	<u>53</u>	<u>3,709,325</u>	<u>52</u>	3410 Exchange difference from translation of the financial statements of foreign operations	(2,158)	-	(1,338)	-
Total assets	<u>\$ 6,615,441</u>	<u>100</u>	<u>7,101,717</u>	<u>100</u>	3420 Unrealized gains or losses on financial assets at fair value through other comprehensive income	(141,149)	(2)	48,342	1
					Total equity attributable to owners of the parent company	3,443,761	52	3,556,895	50
					36xx Non-controlling interests	388,513	6	424,171	6
					Total equity	<u>3,832,274</u>	<u>58</u>	<u>3,981,066</u>	<u>56</u>
					Total liabilities and equity	<u>\$ 6,615,441</u>	<u>100</u>	<u>7,101,717</u>	<u>100</u>

Chairman: Hung-Jen Yang



(please refer to the attached Notes to the Consolidated Financial Report for details)

Manager: Ching-Wen Liu



Chief Accounting Officer: Ya-Mei Huang



ShareHope Medicine Co., Ltd. and its subsidiaries
Consolidated Statement of Comprehensive Income
January 1 to December 31, 2025 and 2024



Unit: NT\$ thousand

	2025		2024	
	Amount	%	Amount	%
4000 Operating revenue (Notes 6(26) and 7)	\$ 4,357,867	100	4,325,831	100
5000 Operating costs (Notes 6(7), (11), (12), (22) and 7)	<u>(3,648,854)</u>	<u>(84)</u>	<u>(3,611,427)</u>	<u>(83)</u>
Gross profit	<u>709,013</u>	<u>16</u>	<u>714,404</u>	<u>17</u>
Operating expenses (Notes 6(4), (11), (12), (19), (22), and 7):				
6100 Marketing expenses	(195,389)	(4)	(241,004)	(6)
6200 Administrative expenses	(422,772)	(10)	(486,531)	(12)
6300 R&D expenses	(5,615)	-	(11,815)	-
6235 Losses on expected credit impairment	(4,423)	-	(10,947)	-
Total operating expenses	<u>(628,199)</u>	<u>(14)</u>	<u>(750,297)</u>	<u>(18)</u>
6500 Not other income and expenses (Notes 6(28) and 7)	90,041	2	214,382	5
Net operating income	<u>170,855</u>	<u>4</u>	<u>178,489</u>	<u>4</u>
Non-operating income and expenses (Notes 6(19) and (29)):				
7100 Interest income	12,222	-	10,533	-
7010 Other income	47,380	1	78,235	2
7020 Other gains and losses	(31,271)	(1)	(35,440)	(1)
7050 Finance costs	(47,811)	(1)	(58,342)	(1)
7770 Share of (losses) gains of affiliates recognized by the equity method	(1,225)	-	435	-
Total non-operating income and expenses	<u>(20,705)</u>	<u>(1)</u>	<u>(4,579)</u>	<u>-</u>
7900 Net income before tax	150,150	3	173,910	4
7950 Income tax expenses (Note 6(23))	<u>(38,253)</u>	<u>(1)</u>	<u>(51,512)</u>	<u>(1)</u>
Net income for the period	<u>111,897</u>	<u>2</u>	<u>122,398</u>	<u>3</u>
8300 Other comprehensive income (Notes 6(23) and (24)):				
8310 Items not reclassified to profit or loss				
8311 Remeasurement amount of defined benefit plans	749	-	1,509	-
8316 Unrealized valuation profits and losses on equity instrument investments at fair value through other comprehensive income	(247,333)	(5)	(81,994)	(2)
8349 Less: income taxes related to non-reclassified items	(53,372)	(1)	(2,924)	-
Total items not reclassified to profit or loss	<u>(193,212)</u>	<u>(4)</u>	<u>(77,561)</u>	<u>(2)</u>
8360 Items that may be reclassified to profit or loss subsequently				
8361 Exchange difference from translation of the financial statements of foreign operations	(1,749)	-	1,883	-
8399 Less: income taxes related to items that may be reclassified	(314)	-	356	-
Total items that may be reclassified to profit or loss subsequently	<u>(1,435)</u>	<u>-</u>	<u>1,527</u>	<u>-</u>
8300 Other comprehensive income for the period	<u>(194,647)</u>	<u>(4)</u>	<u>(76,034)</u>	<u>(2)</u>
8500 Total comprehensive income for this period	<u>\$ (82,750)</u>	<u>(2)</u>	<u>46,364</u>	<u>1</u>
Net profit (loss) attributable to (Note 6(10)):				
8610 Owners of the parent company	\$ 141,727	3	200,097	5
8620 Non-controlling interests	<u>(29,830)</u>	<u>(1)</u>	<u>(77,699)</u>	<u>(2)</u>
	<u>\$ 111,897</u>	<u>2</u>	<u>122,398</u>	<u>3</u>
Total comprehensive income attributable to (Note 6(10)):				
8710 Owners of the parent company	\$ (48,330)	(1)	125,174	3
8720 Non-controlling interests	<u>(34,420)</u>	<u>(1)</u>	<u>(78,810)</u>	<u>(2)</u>
	<u>\$ (82,750)</u>	<u>(2)</u>	<u>46,364</u>	<u>1</u>
Earnings per share (NT\$) (Note 6(25))				
9750 Basic earnings per share	<u>\$ 1.03</u>		<u>1.45</u>	
9850 Diluted earnings per share	<u>\$ 1.03</u>		<u>1.45</u>	

Chairman: Hung-Jen Yang



Please refer to the attached Notes to the Consolidated Financial Report for details)

Manager: Ching-Wen Liu



Chief Accounting Officer: Ya-Mei Huang



ShareHope Medicine Co., Ltd. and its subsidiaries
Consolidated Statement of Changes in Equity
January 1 to December 31, 2025 and 2024



Unit: NT\$ thousand

	Ordinary share capital	Additional paid-in capital	Legal reserves	Undistributed earnings	Exchange difference from translation of the financial statements of foreign operations	Unrealized gains or losses on financial assets at fair value through other comprehensive income	Total equity attributable to owners of the parent company	Non- controlling interests	Total equity
Balance on January 1, 2024	\$ 1,260,443	1,155,834	216,895	732,111	(2,507)	125,160	3,487,936	467,523	3,955,459
Net income for the period	-	-	-	200,097	-	-	200,097	(77,699)	122,398
Other comprehensive income for the period	-	-	-	726	1,169	(76,818)	(74,923)	(1,111)	(76,034)
Total comprehensive income for this period	-	-	-	200,823	1,169	(76,818)	125,174	(78,810)	46,364
Allocation and distribution of earnings:									
Appropriation of legal reserve	-	-	12,114	(12,114)	-	-	-	-	-
Common share cash dividend	-	-	-	(50,418)	-	-	(50,418)	(3,446)	(53,864)
Ordinary share stock dividend	50,418	-	-	(50,418)	-	-	-	-	-
Changes in ownership interests in subsidiaries	-	(5,797)	-	-	-	-	(5,797)	(4,274)	(10,071)
Non-controlling interests	-	-	-	-	-	-	-	43,178	43,178
Balance on December 31, 2024	1,310,861	1,150,037	229,009	819,984	(1,338)	48,342	3,556,895	424,171	3,981,066
Net income for the period	-	-	-	141,727	-	-	141,727	(29,830)	111,897
Other comprehensive income for the period	-	-	-	254	(820)	(189,491)	(190,057)	(4,590)	(194,647)
Total comprehensive income for this period	-	-	-	141,981	(820)	(189,491)	(48,330)	(34,420)	(82,750)
Allocation and distribution of earnings:									
Appropriation of legal reserve	-	-	20,082	(20,082)	-	-	-	-	-
Common share cash dividend	-	-	-	(65,543)	-	-	(65,543)	(3,010)	(68,553)
Ordinary share stock dividend	65,543	-	-	(65,543)	-	-	-	-	-
Changes in ownership interests in subsidiaries	-	739	-	-	-	-	739	1,949	2,688
Non-controlling interests	-	-	-	-	-	-	-	(177)	(177)
Balance on December 31, 2025	\$ 1,376,404	1,150,776	249,091	810,797	(2,158)	(141,149)	3,443,761	388,513	3,832,274

Chairman: Hung-Jen Yang



(please refer to the attached Notes to the Consolidated Financial Report for details)

Manager: Ching-Wen Liu



Chief Accounting Officer: Ya-Mei Huang



ShareHope Medicine Co., Ltd. and its subsidiaries

Consolidated Cash Flow Statement

January 1 to December 31, 2025 and 2024

Unit: NT\$ thousand

	2025	2024
Cash flows from (used in) operating activities:		
Net income before tax for the period	\$ 150,150	173,910
Items adjusted:		
Income and expense items		
depreciation expense	245,588	282,424
Amortization expenses	22,727	25,140
Losses on expected credit impairment	4,423	10,947
Net losses (gains) on financial assets at fair value through profit or loss	3,701	(8,316)
Interest expenses	47,811	58,342
Interest income	(12,222)	(10,533)
Dividend income	(4,252)	(47,074)
Share of (gains) losses of affiliates recognized by the equity method	1,225	(435)
Gains on disposal and retirement of properties, plants and equipment	(4,640)	(18,358)
Gains on the disposal of investment property	-	(117,283)
Loss from disposal of intangible assets	107	-
Gains on disposal of subsidiaries' investments	(74)	(965)
Impairment losses on non-financial assets	1,258	-
Unrealized foreign exchange gains	-	(848)
Lease modification gains	(9,021)	(236)
Losses on disposal of property, plant and equipment	-	41,646
Total income and expense items	296,631	214,451
Changes in assets/liabilities related to operating activities:		
Notes receivable (including related parties)	4,137	953
Accounts receivable (including related parties)	40,571	123,661
Lease payments receivable (including related parties)	31,232	19,345
Other receivables (including related parties)	26,571	(32,873)
Inventories	399	3,860
Prepayments	1,106	6,299
Other current assets	7,488	25
Notes payable (including related parties)	(12,802)	(76,214)
Accounts payable (including related parties)	16,338	(79,913)
Other payables (including related parties)	(102,619)	(2,515)
contract liability	(31,560)	36,414
Other current liabilities	(8,258)	4,083
Net defined benefit liabilities	(83)	(1,373)
Total net changes in assets and liabilities related to operating activities	(27,480)	1,752
Cash inflow from operation	419,301	390,113
Interests received	12,222	10,533
Interests paid	(47,992)	(57,408)
Income taxes paid	(19,406)	(76,563)
Net cash inflow from operating activities	364,125	266,675

(Please refer to the attached Notes to the Consolidated Financial Statements for details)

Chairman:
Hung-Jen Yang



Manager:
Ching-Wen Liu



Chief Accounting Officer:
Ya-Mei Huang



ShareHope Medicine Co., Ltd. and its subsidiaries
Consolidated Cash Flow Statement (Continued)
January 1 to December 31, 2025 and 2024

Unit: NT\$ thousand

	2025	2024
Cash flows from (used in) investing activities:		
Acquisition of financial assets at fair value through other comprehensive income	\$ (9,614)	(42,510)
Capital returned due to capital reduction in financial assets at fair value through other comprehensive income	15,028	4,802
Acquisition of long-term equity method investments	(20,000)	(1,500)
Acquisition of financial assets at fair value through profit or loss	(2,228)	-
(Acquisition) Disposal of financial assets at amortized cost	(116,190)	10,253
Disposal of subsidiaries	-	2,808
Acquisition of property, plant and equipment	(123,980)	(83,071)
Disposal of property, plant and equipment	10,762	58,110
Increase in refundable deposits	(114,892)	(36,730)
Decrease in other receivables-related parties	-	30,491
Acquisition of intangible assets	(7,827)	(9,952)
Disposal of intangible assets	165	-
Loss (gain) on disposal of investment properties	240,000	53,148
Decrease in other non-current assets	1,269	4,328
Dividends received	6,441	44,931
Net cash inflow (outflow) in investing activities	(121,066)	35,108
Cash flows from (used in) financing activities:		
(Decrease) increase in short-term loans	(1,716)	25,620
Decrease in short-term bills payable	(55,000)	-
Borrowing of long-term loans	836,000	2,550
Repayment of long-term loans	(954,726)	(119,042)
(Decrease) increase in deposits received	(4,808)	150
Lease principal payment	(110,897)	(117,236)
Distribution of cash dividends	(68,553)	(53,864)
Buyback cost of treasury stock	-	(9,000)
Changes in non-controlling interests	(177)	43,607
Net cash outflow from financing activities	(359,877)	(227,215)
Impact of exchange rate changes on cash and cash equivalents	(4,131)	2,045
(Decrease) increase in cash and cash equivalents for the period	(120,949)	76,613
Balance of cash and cash equivalents at the beginning of the period	1,459,635	1,383,022
Balance of cash and cash equivalents at the end of the period	\$ 1,338,686	1,459,635

(Please refer to the attached Notes to the Consolidated Financial Statements for details)

Chairperson: Hung-jen Yang

Manager: Ching-wen Liu

Chief Accounting Officer: Ya-mei Huang



Independent Auditors' Report

Submitted to the Board of Directors of ShareHope Medicine Co., Ltd. and subsidiaries for review

Audit opinion

We have audited the Balance Sheet of ShareHope Medicine Co., Ltd. on December 31, 2025 and 2024, and the Statement of Comprehensive Income, Statement of Changes in Equity, Cash Flow Statement and Notes to Parent Company Only Financial Statements (including the Summary of Major Accounting Policies) from January 1 to December 31, 2025 and 2024.

In our opinion, the Parent Company Only Financial Statements referred to above have been prepared, in all material respects, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and are sufficient to adequately express the financial position of ShareHope Medicine Co., Ltd. on December 31, 2025 and 2024 as well as its financial performance and cash flows from January 1 to December 31, 2025 and 2024.

Foundation of the Audit Opinion

The independent auditor performed the audit in compliance with the rules governing the certification of financial statements by entrusted independent auditors and the auditing standards. His responsibilities specified in these standards will be further explained in the section about independent auditors' responsibilities in auditing the Parent Company Only Financial Statements. The personnel subject to independence standards in the accounting firm, to which the said independent auditor is affiliated, have maintained independent from ShareHope Medicine Co., Ltd. in accordance with the CPA Professional and Ethical Guidelines, and have fulfilled other obligations under the Guidelines. We believe that we have obtained sufficient and appropriate audit evidence as the basis for expressing our audit opinion.

Key Audit Matters

Key audit matters refer to matters of greatest importance to the audit of the Parent Company Only Financial Statements of ShareHope Medicine Co., Ltd. for 2025 based on our professional judgment. Such items have been considered in the course of auditing the Parent Company Only Financial Statements and forming the audit opinions, and the independent auditor determines that the following key audit item shall be communicated in the audit report:

Revenue recognition

For the accounting policies for revenue recognition and related disclosure information, please refer to Note 4(14), Note 6(22), and Note 7(3) of the Parent Company Only Financial Statements.

Explanation on key audit items:

The operating revenue of ShareHope Medicine Co., Ltd. is a matter of concern to users of the financial statements and the competent authorities, and the Group's main sales customers are related parties of its medical system, whose operating revenue has a significant impact on the Parent Company Only Financial Statements. Accordingly, revenue recognition is among the important items to be evaluated by the independent auditor in the audit of the Parent Company Only Financial Statements of ShareHope Medicine Co., Ltd.

Corresponding audit procedures:

The main audit procedures adopted by the independent auditor for the key audit items mentioned above include:

- Based on the understanding of the sales-related internal control procedures of ShareHope Medicine Co., Ltd., establish internal control audit procedures in response to the risks generated thereof, in order to identify and evaluate the effectiveness of the internal control over sales transactions made by ShareHope Medicine Co., Ltd. with its related parties.
- Obtain sales revenue details from the management, confirm the completeness of the details, select adequate samples from the revenue details of main sales transactions with related parties, and review relevant vouchers and verify the delivery of goods and receipt of payments, so as to confirm whether the revenues are recognized after relevant obligations are fulfilled as well as the authenticity of revenue recognition.
- Inspect whether there are major discounts or returns of sales revenue subsequent to the sales transactions and evaluate the authenticity of the sales revenue.
- Send a letter of inquiry to relevant parties and confirm whether the recorded revenue is consistent with the transaction amount or has been adjusted appropriately.

Responsibilities of the management and governing body for the Parent Company Only Financial Report

The responsibility of the management is to prepare fairly presented Parent Company Only Financial Statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and to maintain necessary internal control over the preparation of the Parent Company Only Financial Statements, so as to ensure no occurrence of material false statements due to fraud or error in the Parent Company Only Financial Statements.

The responsibility of the management in the preparation of the Parent Company Only Financial Statements also includes the evaluation of the ability of ShareHope Medicine Co., Ltd. to continue business, the disclosure of related items, and the adoption of the accounting basis for continuation of the business, unless the management intends to liquidate ShareHope Medicine Co., Ltd. or close business, or there is no practical alternative to liquidation or close of the business.

The governing body (including the Audit Committee) of ShareHope Medicine Co., Ltd. is responsible for supervising the financial reporting process.

Responsibilities of the independent auditor for auditing the Parent Company Only Financial Statements

The purpose of the independent auditor's audit of the Parent Company Only Financial Statements is to obtain reasonable assurance as to whether there are material false statements due to fraud or error in the Parent Company Only Financial Statements, and to issue an audit report. Reasonable assurance refers to the high degree of certainty. Nevertheless, there is no guarantee that the material false statements in the Parent Company Only Financial Statements will necessarily be detected merely based on the audit work conducted in compliance with the auditing standards. False statements may result from frauds or errors. False statements of several amounts or total amounts are considered material if they can reasonably be expected to affect the economic decisions made by users of the Parent Company Only Financial Statements.

The independent auditor performs professional judgment and professional skepticism when conducting an audit in accordance with the auditing standards. The independent auditor also undertakes the following tasks:

1. Identify and evaluate the risk of material false statements due to frauds or errors in the Parent Company Only Financial Statements, formulate and implement appropriate countermeasures for the risk evaluated, and obtain sufficient and appropriate audit evidence as the basis for audit opinions. Since fraud may involve collusion, forgery, intentional omission, false statements, or overstepping internal control, the risk of the failure to detect material false statements due to frauds is higher than that due to errors.
2. Obtain necessary understanding of the internal control essential to the audit, so as to formulate the appropriate audit procedures for the current situation, for all that the purpose is not to give opinions on the effectiveness of the internal control of ShareHope Medicine Co., Ltd.
3. Evaluate the appropriateness of the accounting policies adopted by the management, as well as the reasonability of the accounting estimates and related disclosures made by them.
4. Draw conclusions on the appropriateness of the management's adoption of the accounting basis for continuation of the business, as well as whether there are significant uncertainties in events or situations that may give rise to material doubts about the ability of ShareHope Medicine Co., Ltd. to continue its business, based on the audit evidences obtained. If the independent auditor believes that there are significant uncertainties in such events or situations, he shall remind users of the Consolidated Financial Statements to pay attention to the disclosures about the Parent Company Only Financial Statements, or revise the audit opinions when such disclosures are inappropriate. The independent auditor's conclusions are based on the audit evidences obtained up to the date of the audit report. However, ShareHope Medicine Co., Ltd. may lose the ability to continue the business due to future events or situations.
5. Evaluate the overall statements, structure, and contents of the Parent Company Only Financial Statements (including relevant notes), and whether relevant transactions and events are fairly presented in the Parent Company Only Financial Statements.

6. Obtain sufficient and appropriate audit evidence for the financial information of the investees applying the equity method to give opinions on the Parent Company Only Financial Statements. The independent auditor is responsible for guiding, supervising, and executing the audit work, and for issuing audit opinions on the ShareHope Medicine Co., Ltd.

The items on which the independent auditor has communicated with the governing body include the planned scope and time of the audit work, as well as major audit findings (including significant deficiencies in internal control identified in the course of the audit).

The independent auditor has also provided the governing body with the statement that the personnel subject to independence standards in the accounting firm, to which the independent auditor is affiliated, have complied with the CPA professional and ethical guidelines regarding independence, and has communicated with the governing body on all relationships and other items that may be considered to affect the independence of independent auditors (including relevant protective measures).

We decided on the key matters to be audited in the Parent Company Only Financial Statements of ShareHope Medicine Co., Ltd. for 2025 based on the matters on which we communicated with the governing body. The independent auditor has stated such items in the Independent Auditors' Report, unless some specific items are prohibited from disclosure according to laws and regulations, or the independent auditor decides not to communicate some items in the Independent Auditors' Report under extremely rare circumstances where it can be reasonably expected that the negative impact of such communication will outweigh the public interest it brings.

KPMG Taiwan

寇惠桓

Astor Kou



CPAs:

鄧永頤

Sinney Kuo



Number of documents approved and certified by the securities regulatory

Tai-Tsai-Zheng-(6)-Zi-0930106739
Jin-Kuan-Zheng-Shen-Zi-1040003949

March 13, 2026

ShareHope Medicine Co., Ltd.

Balance sheet

December 31, 2025 and 2024

Unit: NT\$ thousand



Assets	2025.12.31		2024.12.31		Liabilities and equity	2025.12.31		2024.12.31	
	Amount	%	Amount	%		Amount	%	Amount	%
Current assets:					Current liabilities:				
1100 Cash and cash equivalents (Note 6(1))	\$ 948,146	18	984,469	18	2150 Notes payable	\$ 1,214	-	5,600	-
1110 Financial assets at fair value through profit or loss - current (Note 6(2))	10,769	-	10,610	-	2170 Accounts payable	515,740	10	498,660	9
1120 Current financial assets at fair value through other comprehensive income (Note 6(3))	87,264	2	-	-	2180 Accounts payable - related parties (Note 7)	1,017	-	768	-
1150 Notes receivable (Note 6(4) and (22))	787	-	547	-	2200 Other payables (Note 6(17))	98,104	2	134,966	3
1170 Net accounts receivable (Note 6(4), (6) and (22))	66,929	2	67,429	1	2220 Other accounts payable - related parties (Note 7)	837	-	1,614	-
1180 Accounts receivable - related parties, net (Note 6(4), (6), (22), and 7)	1,060,532	20	946,760	17	2230 Income tax liabilities for the period	17,726	-	23,475	-
1200 Other accounts receivable (Note 6(5))	2,409	-	2,810	-	2280 Lease liabilities - current (Note 6(15))	41,092	1	45,295	1
1210 Other accounts receivable - related parties (Note 6(5) and Note 7)	2,779	-	241,225	5	2322 Long-term loans due in one year or one operating cycle (Note 6(14) and 8)	59,714	1	98,769	2
130X Inventories (Note 6(7))	27,241	1	32,907	1	2399 Other current liabilities	24,533	1	19,569	-
1410 Prepayments (Note 7)	1,285	-	1,730	-	! Total current liabilities	759,977	15	828,716	15
1470 Other current assets	384	-	3,908	-	Non-current liabilities:				
Total current assets	2,208,525	43	2,292,395	42	2540 Long-term borrowings (Note 6(14) and 8)	776,286	15	761,436	14
Non-current assets:					2570 Deferred income tax liabilities (Note 6(19))	-	-	17,013	1
1510 Financial assets at fair value through profit or loss - non-current (Note 6(2))	24,210	-	27,853	-	2580 Lease liabilities - non-current (Note 6(15))	211,770	4	250,982	5
1517 Financial assets at fair value through other comprehensive income - non-current (Note 6(3))	275,773	5	580,750	11	2640 Net defined benefit liabilities - non-current (Note 6(18))	7,868	-	7,267	-
1536 Financial assets at amortized cost - non-current (Note 8)	30,000	1	30,000	1	2645 Deposits received (Note 7)	8,286	-	15,859	-
1550 Equity method investments (Note 6(8))	512,765	10	542,708	10	! Total non-current liabilities	1,004,210	19	1,052,557	20
1600 Property, plant and equipment (Note 6(10) and Note 8)	1,363,071	26	1,341,865	25	! Total liabilities	1,764,187	34	1,881,273	35
1755 Right-of-use assets (Note 6(11))	239,379	5	283,867	5	Equity (Note 6(9) and (20)):				
1780 Intangible assets (Note 6(12))	8,802	-	4,340	-	3110 Ordinary share capital	1,376,404	26	1,310,861	24
1840 Deferred tax assets (Note 6(19))	46,155	1	7,953	-	3200 Additional paid-in capital	1,150,776	22	1,150,037	21
194D Net long-term finance lease receivables (Note 6(6) and Note 7)	4,819	-	7,517	-	3310 Legal reserves	249,091	5	229,009	4
1990 Other non-current assets (Note 6(13) and 7)	494,449	9	318,920	6	3350 Undistributed earnings	810,797	16	819,984	15
! Total non-current assets	2,999,423	57	3,145,773	58	3410 Exchange difference from translation of the financial statements of foreign operations	(2,158)	-	(1,338)	-
					3420 Unrealized gains or losses on financial assets at fair value through other comprehensive income	(141,149)	(3)	48,342	1
					! Total equity	3,443,761	66	3,556,895	65
					Total liabilities and equity	\$ 5,207,948	100	5,438,168	100
Total assets	\$ 5,207,948	100	5,438,168	100					

Chairman: Hung-Jen Yang



(Please refer to the attached Notes to the Consolidated Financial Statements for details)

Manager: Ching-Wen Liu



Chief Accounting Officer: Ya-Mei Huang



ShareHope Medicine Co., Ltd.
Statement of Comprehensive Income
January 1 to December 31, 2025 and 2024

Unit: NT\$ thousand

	2025		2024	
	Amount	%	Amount	%
4000 Operating revenue (Notes 6(22) and 7)	\$ 2,391,181	100	2,408,310	100
5000 Operating costs (Notes 6(7), (10), (11), (12), (15), (18) and Note 7)	(2,053,376)	(86)	(2,047,004)	(85)
Gross profit	<u>337,805</u>	<u>14</u>	<u>361,306</u>	<u>15</u>
Operating expenses (Note 6(4), (10), (11), (12), (15), (18), (23) and Note 7):				
6100 Marketing expenses	(17,078)	(1)	(16,308)	(1)
6200 Administrative expenses	(153,673)	(6)	(164,984)	(7)
6450 Expected credit impairment (reversal gain) loss	218	-	(3)	-
I Total operating expenses	<u>(170,533)</u>	<u>(7)</u>	<u>(181,295)</u>	<u>(8)</u>
6500 Net other income and expenses (Notes 6(24) and 7)	45,109	2	155,922	7
I Total other income and expenses	<u>45,109</u>	<u>2</u>	<u>155,922</u>	<u>7</u>
Net operating income	<u>212,381</u>	<u>9</u>	<u>335,933</u>	<u>14</u>
Non-operating income and expenses (Note 6(2), (8), (15) and (25), and Note 7):				
7100 Interest income	7,697	-	6,447	-
7010 Other income	11,472	-	53,134	2
7020 Other gains and losses	(3,750)	-	8,319	-
7050 Finance costs	(27,604)	(1)	(35,441)	(1)
7070 Share of profits and losses of subsidiaries and affiliates recognized by the equity method	(24,431)	(1)	(120,168)	(5)
I Total non-operating income and expenses	<u>(36,616)</u>	<u>(2)</u>	<u>(87,709)</u>	<u>(4)</u>
7900 Net income before tax	175,765	7	248,224	10
7950 Income tax expense (Note 6(19))	(34,038)	(1)	(48,127)	(2)
Net income for the period	<u>141,727</u>	<u>6</u>	<u>200,097</u>	<u>8</u>
8300 Other comprehensive income (Note 6(18), (19) and (20)):				
8310 Items not reclassified to profit or loss				
8311 Remeasurement amount of defined benefit plans	(370)	-	(49)	-
8316 Unrealized valuation profits and losses on equity instrument investments at fair value through other comprehensive income	(241,114)	(10)	(68,390)	(3)
8330 Share of other comprehensive income of subsidiaries and affiliates recognized by the equity method	(1,349)	-	(10,888)	-
8349 Less: income taxes related to non-reclassified items	(53,596)	(2)	(3,235)	-
I Total items not reclassified to profit or loss	<u>(189,237)</u>	<u>(8)</u>	<u>(76,092)</u>	<u>(3)</u>
8360 Items that may be reclassified to profit or loss subsequently				
8361 Exchange difference from translation of the financial statements of foreign operations	(152)	-	953	-
8380 Share of other comprehensive income of subsidiaries recognized by the equity method	(698)	-	407	-
8399 Less: income taxes related to items that may be reclassified	(30)	-	191	-
I Total items that may be reclassified to profit or loss subsequently	<u>(820)</u>	<u>-</u>	<u>1,169</u>	<u>-</u>
8300 Other comprehensive income for this period (net of tax)	<u>(190,057)</u>	<u>(8)</u>	<u>(74,923)</u>	<u>(3)</u>
8500 Total comprehensive income for this period	<u>\$ (48,330)</u>	<u>(2)</u>	<u>125,174</u>	<u>5</u>
Earnings per share (NT\$) (Note 6(21))				
9750 Basic earnings per share	<u>\$ 1.03</u>		<u>1.45</u>	
9850 Diluted earnings per share	<u>\$ 1.03</u>		<u>1.45</u>	

(Please refer to the attached Notes to the Consolidated Financial Statements for details)

Chairman: Hung-Jen Yang

Manager: Ching-Wen Liu

Chief Accounting Officer: Ya-Mei Huang

ShareHope Medicine Co., Ltd.
 Statement of Changes in Equity
 January 1 to December 31, 2025 and 2024

Unit: NT\$ thousand

	Ordinary share capital	Additional paid- in capital	Legal reserves	Undistributed earnings	Exchange difference from translation of the financial statements of foreign operations	Unrealized gains or losses on financial assets at fair value through other comprehensive income	Total equity
Balance on January 1, 2024	\$ 1,260,443	1,155,834	216,895	732,111	(2,507)	125,160	3,487,936
Net income for the period	-	-	-	200,097	-	-	200,097
Other comprehensive income for the period	-	-	-	726	1,169	(76,818)	(74,923)
Total comprehensive income for this period	-	-	-	200,823	1,169	(76,818)	125,174
Allocation and distribution of earnings:							
Appropriation of legal reserve	-	-	12,114	(12,114)	-	-	-
Common share cash dividend	-	-	-	(50,418)	-	-	(50,418)
Ordinary share stock dividend	50,418	-	-	(50,418)	-	-	-
Changes in ownership interests in subsidiaries	-	(5,797)	-	-	-	-	(5,797)
Balance on December 31, 2024	1,310,861	1,150,037	229,009	819,984	(1,338)	48,342	3,556,895
Net income for the period	-	-	-	141,727	-	-	141,727
Other comprehensive income for the period	-	-	-	254	(820)	(189,491)	(190,057)
Total comprehensive income for this period	-	-	-	141,981	(820)	(189,491)	(48,330)
Allocation and distribution of earnings:							
Appropriation of legal reserve	-	-	20,082	(20,082)	-	-	-
Common share cash dividend	-	-	-	(65,543)	-	-	(65,543)
Ordinary share stock dividend	65,543	-	-	(65,543)	-	-	-
Changes in ownership interests in subsidiaries	-	739	-	-	-	-	739
Balance at December 31, 2025	\$ 1,376,404	1,150,776	249,091	810,797	(2,158)	(141,149)	3,443,761

Chairman: Hung-Jen Yang



(Please refer to the attached Notes to the Consolidated Financial Statements for details)

Manager: Ching-Wen Liu



Chief Accounting Officer: Ya-Mei Huang



ShareHope Medicine Co., Ltd.

Cash Flow Statement

January 1 to December 31, 2025 and 2024

Unit: NT\$ thousand

	2025	2024
Cash flows from (used in) operating activities:		
Net income before tax for the period	\$ 175,765	248,224
Items adjusted:		
Income and expense items		
depreciation expense	143,399	148,076
Amortization expenses	5,217	2,595
Expected credit impairment (reversal gain) loss	(218)	3
Net loss (profit) on financial assets and liabilities measured at fair value through profit or loss	3,712	(8,316)
Interest expenses	27,604	35,441
Interest income	(7,697)	(6,447)
Dividend income	(2,652)	(46,287)
Share of losses of subsidiaries and affiliates recognized by the equity method	24,431	120,168
Gains on disposal and retirement of properties, plants and equipment	(7,286)	(118,256)
Total income and expense items	186,510	126,977
Changes in assets/liabilities related to operating activities:		
Notes receivable (including related parties)	(240)	156
Accounts receivable (including related parties)	(109,147)	113,972
Lease payments receivable (including related parties)	267	9,625
Other receivables (including related parties)	(887)	(514)
Inventories	5,666	9,070
Prepayments (including related parties)	2,430	5,392
Other current assets	3,523	(738)
contract liability	(31,219)	134
Notes payable	(4,386)	(1,800)
Accounts payable (including related parties)	17,163	(139,713)
Other payables (including related parties)	(32,738)	12,686
Other current liabilities	(37)	2,121
Net defined benefit liabilities	231	(1,011)
Total net changes in assets and liabilities related to operating activities	(149,374)	9,380
Cash inflow from operation	212,901	384,581
Interests received	7,697	6,447
Interests paid	(27,731)	(35,479)
Income taxes paid	(55,465)	(74,246)
Net cash inflow from operating activities	137,402	281,303

(Please refer to the attached Notes to the Consolidated Financial Statements for details)

Chairman:
Hung-Jen YangManager:
Ching-Wen LiuChief Accounting Officer:
Ya-Mei Huang

ShareHope Medicine Co., Ltd.
Cash Flow Statement (Continued)
January 1 to December 31, 2025 and 2024

	Unit: NT\$ thousand	
	2025	2024
Cash flows from (used in) investing activities:		
Acquisition of financial assets at fair value through other comprehensive income	\$ (9,614)	(42,510)
Capital returned due to capital reduction in financial assets at fair value through other comprehensive income	13,443	4,040
Acquisition of financial assets at fair value through profit or loss	(228)	-
Acquisition of equity method investments	(20,000)	(45,006)
Disposal of equity method investments	-	893
Acquisition of property, plant and equipment	(114,163)	(42,370)
Disposal of property, plant and equipment	9,954	61,881
Acquisition of intangible assets	(11,480)	(3,179)
Cash inflow from mergers	21,296	-
Loss (gain) on disposal of investment properties	240,000	-
Decrease in other non-current assets	804	933
(Increase) decrease in refundable deposits	(92,092)	9
Dividends received	8,060	44,196
Net cash inflow (outflow) from investing activities	45,980	(21,113)
Cash flows from (used in) financing activities:		
Decrease in short-term loans	(50,000)	(50,000)
Repayment of long-term loans	(54,205)	(95,883)
(Decrease) increase in deposits received	(4,447)	421
Lease principal payment	(45,510)	(47,689)
Distribution of cash dividends	(65,543)	(50,418)
Net cash outflow from financing activities	(219,705)	(243,569)
(Decrease) increase in cash and cash equivalents for the period	(36,323)	16,621
Balance of cash and cash equivalents at the beginning of the period	984,469	967,848
Balance of cash and cash equivalents at the end of the period	\$ 948,146	984,469

(Please refer to the attached Notes to the Consolidated Financial Statements for details)

Chairman:
Hung-Jen Yang



Manager:
Ching-Wen Liu



Chief Accounting Officer:
Ya-Mei Huang



III. Appendix

Appendix: Articles of Incorporation

Chapter One General Provisions

Article 1: The company is organized in accordance with the provisions of the Articles of Incorporation for limited liability companies and is named "ShareHope Medicine Co., Ltd."

Article 2: The business of the company is as follows:

- 01.F108021 Wholesale of western medicine.
- 02.F108011 Wholesale of traditional Chinese medicine.
- 03.F208050 Retailing of Class B finished medicines.
- 04.F108031 Wholesale of medical equipment.
- 05.F108040 Wholesale of cosmetics.
- 06.F208040 Retailing of cosmetics.
- 07.F118010 Information software wholesale industry.
- 08.F401010 International trade industry.
- 09.I103060 Management consulting industry.
- 10.I301010 Information software service industry.
- 11.IC01010 Drug testing industry.
- 12.IZ12010 Manpower dispatching industry.
13. JE01010 Leasing industry.
14. JZ99050 Intermediary service industry.
15. ZZ99999 In addition to the licensed business, it may operate business that is not prohibited or restricted by law.
- 16.F102170 Wholesale of food and miscellaneous goods.
- 17.F203010 Food and beverage retailing.
- 18.F208031 Retailing of medical equipment.
- 19.J901020 General hotel industry

Article 3: When the company invests in another company and becomes a limited liability shareholder, the total investment amount is not restricted by Article 13 of the Articles of Incorporation, which shall not exceed 40% of the paid-in share capital.

Article 4: The company may provide external guaranty for business needs, and shall do so after obtaining the approval of the board of directors in accordance with the company's "Endorsement Guarantee Operation Method".

Article 5: The head office of the company is located in Taoyuan City. When necessary, branch companies can be set up at home and abroad with the resolution of the board of directors.

Chapter II Shares

Article 6: The total capital of the Company is set at NT\$2 billion, divided into 200 million shares, with each share valued at NT\$10, and the Board of Directors is authorized to issue the

shares in installments.

NT\$150,000,000 is reserved in the total capital of the preceding paragraph for the issuance of employee stock option certificates, totaling NT\$150,000,000. Thousands of five million shares, with a value of NT\$10 per share, authorized the board of directors to issue in installments. The company issues employee stock option certificates whose stock option price is lower than the closing price of the common stock of the company on the date of issuance certificate, there should be a shareholders' meeting attended by shareholders representing more than half of the total number of issued shares, and shareholders attending the voting right. After more than two-thirds of the approval, it can be issued. If the company intends to transfer the repurchased shares of the company to its employees at a price lower than the average price of the actual repurchased shares. For workers, prior to the transfer, the most recent shareholder meeting must be attended by shareholders representing more than half of the total number of issued shares, and the consent of more than two-thirds of the voting rights of the attending shareholders shall be obtained.

Article 7: The shares of the company may be exempted from printing certificates. If the company prints stock certificates, they shall be registered stock certificates and shall be issued in accordance with the Articles of Incorporation of the Republic of China and other relevant laws and regulations.

Article 8: The name change and transfer of shares shall not be carried out within 30 days before the regular meeting of shareholders, within 15 days before the extraordinary meeting of shareholders, or within 5 days before the company decides to distribute dividends, bonuses or other benefits. The above-mentioned period shall be calculated from the meeting date or the base date. After the public offering of shares by the company, changes to the records in the shareholder register shall not be made within 60 days before the regular shareholders' meeting or within 30 days before the extraordinary shareholders' meeting. When the company intends to cancel the public offering, it shall submit a resolution of the shareholders' meeting.

Article 9: Shareholders of the company shall handle stock matters such as stock transfer, pledge of rights, report of loss, inheritance, gift, report of loss or change of seal, change of address, etc., in accordance with the Articles of Incorporation and the regulations of the competent securities authority.

Chapter III Shareholders' Meeting

Article 10: There are two types of shareholder meetings: regular meetings and extraordinary meetings. Regular meetings are held at least once a year within six months after the end of each fiscal year. The interim meeting shall be convened according to law when necessary. Unless otherwise provided by the Company Act, the shareholders' meeting referred to in the preceding paragraph shall be convened by the board of directors. The shareholders' meeting of the company may be held by video conference or other methods announced by the central competent authority. Relevant regulations such as the conditions, operating procedures, and other matters to be

complied with for the adoption of a videoconference shareholder meeting, unless otherwise stipulated by the competent authority, shall prevail.

Article 11: When a shareholder is unable to attend the shareholders' meeting for any reason, he or she must issue a power of attorney issued by the company specifying the scope of authorization, sign and seal the entrusting proxy to attend or exercise the voting rights of holding stocks by electronic voting as a shareholder present in person meeting. The standard of attendance by proxy shall be handled in accordance with Article 177 of the Articles of Incorporation.

Article 12: Except as otherwise provided by the Articles of Incorporation and the Articles of Association, the resolution of the shareholders' meeting shall be attended by shareholders representing more than half of the total number of issued shares, and shall be carried out with the consent of more than half of the voting rights of the attending shareholders.

Article 13: Except for the circumstances stipulated in Article 157, Paragraph 3 of the Articles of Incorporation, Article 179 and relevant laws and regulations, each shareholder of the company has one voting right.

Chapter IV Directors and Audit Committee

Article 14: The company has nine to eleven directors, adopts a nomination system for candidates, and the term of office is three years, and is elected by the shareholders meeting who have the capacity to act, and can be re-elected. The election of the directors of the company adopts the single-name accumulative election method. If there is a need to amend this method, it shall be handled in accordance with Article 172 of the Articles of Incorporation and other provisions, and the amendment to the method shall be listed in the reasons for convening the shareholders' meeting chart. After the public offering of the company, the number of independent directors shall not be less than three, and shall not be less than one-fifth of the number of directors. Restrictions, nomination and selection methods, and other matters to be complied with shall be handled in accordance with the relevant regulations of the securities regulatory authority. The company has established an audit committee in accordance with the Securities and Exchange Law, which is composed of all independent directors, one of whom serves as the convener, and at least one of them has accounting or financial expertise. The audit committee's responsibilities, organizational regulations, exercise of powers and other matters to be followed shall be handled in accordance with the regulations of the competent authority. The company may, upon resolution of the board of directors, purchase liability insurance for the directors of the company.

Article 15: When the chairman asks for leave or is unable to exercise his powers for some reason, his agency shall be handled in accordance with the provisions of Article 208 of the Articles of Incorporation.

Article 16: The board of directors shall be organized by directors, and more than two-thirds of the directors shall be present, and more than half of the directors present shall elect a chairman, who shall represent the company externally. When necessary, the board of

directors may add a vice chairman, who shall be elected by the directors according to the method mentioned in the preceding paragraph.

Article 17: The remuneration of all directors shall be based on the degree of participation in the company's operations and the value of their contributions, and the participation. According to the usual standards of the industry, the authorization shall be determined by the board of directors. The traveling expenses of all directors shall be determined by the board meeting.

Article 18: The reason for the convening of the board of directors of the company shall be stated, and the directors shall be notified seven days in advance; however, in case of emergency, the convening may be called at any time. The convening notice of the board of directors can be issued in writing, by fax or by electronic mail (E-mail).

Chapter V Managers

Article 19: The company may set up managers, whose appointment, dismissal and remuneration shall be handled in accordance with Article 29 of the Articles of Incorporation. The general manager shall handle the company's business in accordance with the resolutions of the shareholders' meeting or the board of directors, and shall have the right to manage and sign the company's affairs within the scope of authorization stipulated in the company's articles of association or contract.

Chapter VI Decision

Article 20: The company shall, at the end of each accounting year, make a statement by the board of directors:

1. Business report
2. Financial statements
3. Proposals on profit distribution or loss recovery, etc.

Submit to the regular meeting of shareholders in accordance with the law and request for approval.

Article 21: If the Company generates a profit for the year, it shall allocate 6% to 10% as employee compensation (with no less than 10% allocated to lower-level employees), to be distributed in stock or cash by resolution of the Board of Directors. The distribution shall be made to employees of subsidiaries who meet certain conditions. Based on the aforementioned profit, the Board of Directors shall allocate no more than 3% as director compensation. The distribution of employee and director compensation shall be reported to the shareholders' meeting.

However, if the Company has accumulated losses, it shall reserve funds in advance to offset these losses before allocating employee and director compensation according to the aforementioned proportions.

Article 22: If there is a surplus in the company's annual final accounts, it shall pay taxes in accordance with the law, and after making up for the accumulated losses, an additional percentage. Ten is the statutory surplus reserve, but when the statutory surplus reserve has reached the paid-in capital of the company, it may not be

withdrawn Listed; the rest will be listed or transferred to the special surplus reserve according to laws and regulations; if there is any remaining balance, it will be accumulated together. The accumulated undistributed earnings, the board of directors shall prepare a surplus distribution proposal, and submit to the shareholders' meeting for a resolution on the distribution of shareholder shares dividends. The company's shareholder dividend policy is based on consideration of the company's current and future investment environment, capital needs, After the profit situation, capital structure and future operating needs, take into account the interests of shareholders, balance dividends and the company. Long-term financial planning, etc., are distributed in cash or stocks. Among the annual dividends distributed to shareholders. In principle, the proportion of cash dividends paid shall not be lower than 20% of the total dividends for the year, and the rest. Distributed in the form of stock dividends. However, the actual distribution ratio depends on the actual profit and operating conditions of the year

Chapter VII Supplementary Provisions

Article 23: Matters not specified in the Articles of Association shall be handled in accordance with the provisions of the Articles of Incorporation and other laws and regulations.

Article 24: This constitution was established on September 10, 2003.

The first revision was on April 27, 2005.

The second revision was on October 24, 2005.

The third revision was on December 30, 2005.

The fourth revision was on January 19, 2007.

The fifth revision was on October 31, 2007.

The sixth revision was on January 15, 2008.

The seventh revision was on April 14, 2008.

The eighth revision was on November 01, 2008.

The ninth revision was on June 24, 2009.

The tenth revision was on November 18, 2009.

The eleventh revision was made on June 23, 2010.

The twelfth revision was on October 29, 2010.

The thirteenth revision was made on June 27, 2011.

The fourteenth revision was on June 29, 2012.

The fifteenth revision was on June 20, 2013.

The sixteenth revision was on June 24, 2016.

The seventeenth revision was on June 28, 2017.

The eighteenth revision was made on December 05, 2017.

The nineteenth revision was on June 27, 2018.

The twentieth revision was made on July 29, 2021.

The twenty-one revision was on June 29, 2022

The twenty-two revision was on June 24, 2024

The twenty-two revision was on June 16, 2025

Appendix 2: Current Shareholding of Directors and Supervisors (Before revision)

Article 1. In order to establish a good governance system of the company's shareholders meeting, improve the supervision function and strengthen the management function, this rule is formulated in accordance with Article 5 of the Code of Practice for Corporate Governance of Listed OTC Companies for compliance.

Article 2 The rules of procedure for shareholders of the company shall follow the provisions of these rules, unless otherwise stipulated by laws or articles of association.

Article 3. The shareholders' meeting of the company shall be convened by the board of directors unless otherwise stipulated by laws and regulations.

When a company convenes a video meeting of shareholders, unless otherwise specified in the stock affairs management standards of a company that publicly issues shares, it should be stated in the articles of association and approved by the board of directors, and the video meeting of shareholders should be approved by the board of directors with the attendance and attendance of more than two-thirds of the directors. The resolution shall be carried out if approved by more than half of the directors.

Changes in the method of convening the shareholders' meeting of the company shall be resolved by the board of directors, and shall be implemented no later than the dispatch of the notice of the shareholders' meeting.

The company shall, 30 days before the regular shareholders' meeting or 15 days before the extraordinary shareholders' meeting, submit the notice of the shareholders' meeting, the power of attorney, the reasons and explanations for various proposals, such as the admission proposal, the discussion proposal, the election or dismissal of directors, etc.

The data is made into an electronic file and sent to the Public Information Observatory.

And 21 days before the regular shareholders' meeting or 15 days before the extraordinary shareholders' meeting, the shareholders' meeting manual and meeting supplementary materials, make electronic files and send them to the public information observation station. If the amount reaches NT\$10 billion or more, or if the shareholders' list of shareholders held a regular meeting in the most recent fiscal year and the total shareholding ratio of foreign capital and mainland capital reaches 30% or more, the e-mail should be opened 30 days before the regular shareholders' meeting is completed. File transfer. Fifteen days before the shareholders' meeting, prepare the manual of the shareholders' meeting and supplementary materials for the meeting at any time for shareholders to consult at any time, and display them in the company and its professional stock affairs agency appointed by the company.

On the day of the general meeting of shareholders, the Company shall provide shareholders with reference to the procedural manual and meeting supplementary materials mentioned in the preceding paragraph in the following manner:

1. When the physical shareholder meeting is held, it shall be issued on the spot of the shareholder meeting.
2. When convening a video-assisted shareholders' meeting, it shall be distributed at the site of the shareholders' meeting and sent to the video conference platform as an

electronic file.

3. When convening a video conference, the electronic file shall be sent to the video conference platform.

The notification and announcement shall specify the reason for the convening; the notification may be done electronically if the counterparty agrees.

Appointment or dismissal of directors, change of articles of association, reduction of capital, application for cessation of public offering, directors' non-competition permit, capital increase from surplus, capital increase from public reserves, company dissolution, merger, division, or any of the provisions of Paragraph 1 of Article 185 of the Company Law Matters, Article 26-1 and Article 43-6 of the Securities and Exchange Act, and Article 56-1 and Article 60-2 of the Issuer's Guidelines for Handling the Offering and Issuance of Securities shall be held at the convening. The main content shall be enumerated and explained in the reasons, and shall not be raised as an interim motion.

The reason for the convening of the shareholders' meeting has stated the general re-election of directors and independent directors, and the date of inauguration. After the re-election of the shareholders' meeting is completed, the same meeting shall not change the date of inauguration by temporary motion or other means.

Shareholders who hold more than 1% of the total number of issued shares may submit to the company a resolution for the general meeting of shareholders, and no more than one proposal shall be included in the resolution. In addition, if a proposal proposed by a shareholder falls under any of the circumstances in Item 4 of Article 172-1 of the Company Law, the board of directors may not include it as a proposal. Shareholders may submit suggestive proposals to urge the company to promote public interests or fulfill social responsibilities. The procedure shall be limited to one in accordance with the relevant provisions of Article 172-1 of the Company Law. Not included in the motion.

The company shall announce the acceptance of shareholders' proposals, written or electronic acceptance method, acceptance location, and acceptance period before the stockholders' general meeting closes; the acceptance period shall not be less than ten days.

Proposals proposed by shareholders are limited to 300 words, and those exceeding 300 words will not be included in the proposal; the proposing shareholder should attend the general meeting of shareholders in person or entrust others to participate in the discussion of the proposal.

The company shall notify the proposing shareholders of the results of the handling before the notice date for the convening of the shareholders' meeting, and list the proposals that meet the provisions of this article in the meeting notice. For shareholder proposals that are not included in the proposal, the board of directors shall explain the reasons for not including them at the shareholders' meeting.

Article 4. Shareholders may issue a power of attorney issued by the company at each shareholders' meeting, specifying the scope of authorization, and entrust a proxy to

attend the shareholders' meeting.

A shareholder shall issue a power of attorney, limited to one person, and shall deliver it to the company five days before the shareholders' meeting. If there are duplicate powers of attorney, the one delivered first shall prevail. However, this does not apply to those entrusted before the declaration is revoked.

After the power of attorney is delivered to the company, if the shareholder wishes to attend the shareholders' meeting in person or exercise voting rights in writing or electronically, he or she shall notify the company in writing of the cancellation of the proxy two days before the shareholders' meeting; The voting rights exercised by the person present shall prevail.

After the power of attorney is delivered to the company, shareholders wishing to attend the shareholders' meeting by videoconference shall notify the company in writing of the cancellation of the proxy two days before the shareholders' meeting;

Article 5. The place where the shareholders' meeting is held shall be the location of the company or a place that is convenient for shareholders to attend and is suitable for holding the shareholders' meeting. The starting time of the meeting shall not be earlier than 9:00 am or later than 3:00 pm. , shall fully consider the opinions of independent directors. When the company holds a video-conference shareholders meeting, it is not subject to the restriction on the venue of the preceding paragraph.

Article 6. The company shall specify in the notice of the meeting the time and place of registration of the accepting shareholders, solicitors, and authorized agents (hereinafter referred to as shareholders), and other matters that should be paid attention to. The time for accepting shareholder registration in the preceding paragraph shall be handled at least 30 minutes before the meeting starts; the registration office shall be clearly marked, and adequate and competent personnel shall be assigned to handle it; the shareholders meeting video meeting shall be held 30 minutes before the meeting starts at the shareholders meeting The meeting platform accepts registration, and shareholders who complete the registration are deemed to have attended the shareholders' meeting in person.

Shareholders should present their attendance certificates, attendance cards or other attendance certificates to attend the shareholders' meeting. The company shall not arbitrarily add other certificates to the certificates that shareholders rely on for attendance; the solicitor who is a solicitation letter of attorney shall bring his or her identity certificate , for verification.

The company shall set up a signature book for the attendance of shareholders to sign in, or the attendance card shall be submitted by the attending shareholder to sign in. The company shall deliver the meeting manual, annual report, attendance certificate, speech slips, votes and other meeting materials to the shareholders attending the shareholders' meeting; if there are directors to be elected, the ballots shall be attached. When the government or legal person is the shareholder, the representative attending the shareholders meeting is not limited to one person. When a legal person is entrusted to attend a shareholders' meeting, it may only designate one representative to attend.

If the shareholders meeting is convened by videoconference, shareholders who wish to attend by videoconference shall register with the company two days before the shareholders meeting.

If the shareholders' meeting is held by video conference, the company shall upload the procedure manual, annual report and other relevant materials to the shareholders' meeting video conference platform at least 30 minutes before the start of the meeting, and continue to disclose them until the end of the meeting.

Article 6-1. When the company convenes a shareholders meeting via videoconference, it shall specify the following items in the shareholders meeting convening notice:

1. Shareholders' participation in video conferences and methods for exercising their rights.

2. How to deal with obstacles caused by natural disasters, accidents, or other force majeure events to the video conferencing platform or to participate in video conferences, including at least the following items:

(1) The time at which the meeting must be postponed or resumed due to the occurrence of previous obstacles that cannot be eliminated, and the date when the meeting must be postponed or continued.

(2) Shareholders who have not registered to participate in the original shareholders' meeting via video conference shall not participate in the postponed or continued meeting.

(3) To convene a video-assisted shareholders' meeting, if the video conference cannot be continued, after deducting the number of shares attending the shareholders' meeting via video conference, the total number of shares attended reaches the statutory quota for the shareholders' meeting, the shareholders' meeting should continue and participate in the video conference. Shareholders, whose number of shares attended shall be included in the total number of shareholders' shares present, shall be deemed to have abstained from voting on all proposals at the shareholders' meeting.

(4) How to deal with the situation where all the motions have been announced and no provisional motions have been made.

3. Convene a video conference of shareholders and specify appropriate alternative measures for shareholders who would have difficulty participating via video conference. Except for the circumstances stipulated in Paragraph 6 of Article 44-9 of the Standards for Handling Stock Affairs of Companies with Public Issuance of Stocks, shareholders should at least be provided with connection equipment and necessary assistance, and the period during which shareholders can apply to the company and other relevant matters should be noted. matter..

Article 7. If the shareholders' meeting is convened by the board of directors, the chairman shall be the chairman. When the chairman asks for leave or is unable to exercise his powers for some reason, the vice chairman shall act as his proxy. Therefore, when the power cannot be exercised, the chairman shall designate a managing director to act as an agent; if there is no managing director, designate a director to act as an agent; if the chairman does not designate an agent, the managing director or the directors shall

recommend a person to act as the agent.

The chairman referred to in the preceding paragraph shall be the executive director or a director acting as an agent, and the executive director or director who has served for more than six months and understands the company's financial and business conditions shall serve as the chairman. The same applies if the chairman is the representative of the corporate director.

The chairman of the board of directors should preside over the shareholders' meeting convened by the board of directors in person, and more than half of the directors of the board of directors should attend in person, and at least one member of various functional committees should attend the meeting, and the attendance status should be recorded in the minutes of the shareholders' meeting.

If the shareholders' meeting is convened by a person with the right to convene other than the board of directors, the person with the right to convene shall act as the chairman.

The company may appoint lawyers, accountants or related personnel to attend the shareholders' meeting.

Article 8. The company shall record and video record the whole process of the shareholders meeting.

The audio-visual materials mentioned in the preceding paragraph shall be kept for at least one year. However, if a shareholder files a lawsuit in accordance with Article 189 of the Company Law, it shall be preserved until the lawsuit is concluded.

If the shareholders' meeting is held by video conference, the company shall keep records of shareholders' registration, registration, registration, questioning, voting, and company vote counting results, etc., and record and video the entire process of the video conference continuously.

The company shall properly keep the materials and audio and video recordings in the preceding paragraph during the duration of the company's existence, and provide the audio and video recordings to the person entrusted to handle the video conferencing affairs for storage.

If the shareholders' meeting is held by video conference, the company should make audio and video recordings of the background operation interface of the video conference platform.

Article 9 Attendance at the shareholders' meeting shall be calculated based on shares. The number of shares attended is calculated based on the number of shares registered on the signature book or attendance card and video conferencing platform, plus the number of shares that exercise voting rights in written or electronic means.

When the meeting time has expired, the chairman shall immediately announce the opening of the meeting, and at the same time announce relevant information such as the number of non-voting rights and the number of shares present. However, when shareholders representing more than half of the total number of issued shares are not present, the chairman may announce the postponement of the meeting. The number of postponements is limited to two, and the total delay time shall not exceed one hour. If

there are still not enough shareholders representing more than one-third of the total issued shares to attend after two delays, the chairman will announce the adjournment; if the shareholders' meeting is held by video conference, the company shall also announce the adjournment on the shareholders' meeting video conference platform. If the preceding paragraph is postponed twice and the amount is still insufficient and there are shareholders representing more than one-third of the total issued shares present, a false resolution may be made in accordance with Article 175, Paragraph 1 of the Company Law, and the false resolution shall be notified to all parties. Shareholders shall convene a shareholders' meeting again within one month; if the shareholders' meeting is convened by videoconference, shareholders who wish to attend by videoconference shall re-register with the company in accordance with Article 6. Before the end of the current meeting, if the number of shares represented by the attending shareholders reaches more than half of the total number of issued shares, the chairman may resubmit the false resolution made to the shareholders' meeting for voting in accordance with Article 174 of the Company Law.

Article 10. If the shareholders' meeting is convened by the board of directors, the agenda shall be determined by the board of directors. Relevant proposals (including temporary motions and amendments to original proposals) shall be voted on case by case. The resolution cannot be changed.

If the shareholders' meeting is convened by a person other than the board of directors who has the right to convene, the provisions of the preceding paragraph shall apply *mutatis mutandis*.

Before the conclusion of the agenda (including temporary motions) scheduled in the preceding two items, the chairman shall not announce the adjournment of the meeting without a resolution; if the chairman violates the rules of procedure and announces the adjournment, other members of the board of directors shall promptly assist the attending shareholders in accordance with legal procedures to More than half of the voting rights of the present shareholders agree to elect one person as the chairman to continue the meeting.

The chairman shall give full explanations and opportunities for discussion on proposals and amendments or interim motions proposed by shareholders. When he thinks that the proposals have reached the level that can be voted on, he may announce the suspension of discussions, put them up for voting, and arrange adequate voting time.

Article 11. Before attending a shareholder's speech, a statement must be filled out to indicate the gist of the speech, shareholder account number (or attendance card number) and account name, and the order of speeches shall be determined by the chairman. Shareholders attending the meeting who only put forward speech slips but did not make a speech shall be deemed as having not made a speech. If the content of the speech is inconsistent with the record of the speech, the content of the speech shall prevail. Each shareholder's speech on the same proposal shall not exceed two times without the consent of the chairman, and each time shall not exceed five minutes.

However, if a shareholder's speech violates the regulations or exceeds the scope of the topic, the chairman may stop the speech. When a shareholder present speaks, other shareholders are not allowed to interfere with the speech unless the chairman and the shareholder who speaks agree, and the chairman should stop the violation. When a legal person shareholder appoints two or more representatives to attend the shareholders' meeting, only one person may speak on the same proposal. After attending shareholders' speeches, the chairman may reply in person or by designating relevant personnel. If the shareholders meeting is convened by video conference, shareholders who participate in the video conference may ask questions in text on the shareholders meeting video conference platform after the chairman announces the meeting and before the meeting is closed. The number of questions for each proposal shall not exceed two times. The limit is 200 characters, and the provisions of items 1 to 5 do not apply.

If the question in the preceding paragraph does not violate the regulations or exceed the scope of the proposal, it is advisable to disclose the question on the video conferencing platform of the shareholders meeting for public awareness.

Article 12. Voting at the shareholders' meeting shall be based on shares.

The number of shares of non-voting shareholders shall not be included in the total number of issued shares for the resolutions of the shareholders' meeting.

Shareholders who have their own interests in matters at the meeting that may harm the interests of the company may not participate in voting, and may not exercise their voting rights on behalf of other shareholders.

The number of shares for which voting cannot be exercised in the preceding paragraph shall not be included in the number of voting rights of shareholders present.

Except for a trust enterprise or a stock affairs agency approved by the competent securities authority, when one person is entrusted by two or more shareholders at the same time, the voting rights of the proxy shall not exceed 3% of the total number of issued shares. Not counted.

Article 13. Shareholders have one voting right for each share; however, this does not apply to those who are restricted or have no voting rights listed in Item 2 of Article 179 of the Company Law.

When the company convenes a general meeting of shareholders, voting rights shall be exercised electronically and may be exercised in written form; the method of exercise shall be specified in the notice convening the general meeting of shareholders. Shareholders who exercise their voting rights in writing or electronically shall be deemed to have attended the shareholders' meeting in person. However, it shall be regarded as abstaining from voting on the temporary motion of the shareholders meeting and the amendment of the original motion.

Therefore, the company should avoid filing interim motions and amendments to original motions.

For those who exercise their voting rights in writing or electronically in the

preceding paragraph, their declaration of intent shall be delivered to the company two days before the shareholders' meeting. However, this does not apply to those who express their intention before the declaration is revoked.

After shareholders exercise their voting rights in writing or electronically, if they want to attend the shareholders' meeting in person or via video, they should revoke the declaration of intention to exercise voting rights in the preceding paragraph in the same way as exercising voting rights two days before the shareholders' meeting; Voting rights exercised electronically shall prevail. If voting rights are exercised in written or electronic means and a proxy is authorized to attend the shareholders' meeting with a power of attorney, the voting rights performed by the proxy shall prevail.

Unless otherwise provided for by the Company Law and the Articles of Association of the company, voting on proposals shall be passed with the consent of more than half of the voting rights of the shareholders present. When voting, the chairman or his designee shall announce the total number of voting rights of shareholders present on a case-by-case basis. If the chairman consults with all the shareholders present and has no objection to the proposal, it shall be deemed passed, and its effect is the same as that of voting by ballot; if there is any objection, it shall be voted by ballot in accordance with the provisions of the preceding paragraph.

When there is an amendment or alternative to the same proposal, the chairman shall determine the order of voting with the original proposal. If one of the proposals has been passed, the other proposals shall be deemed to be rejected, and there is no need to vote again.

The scrutiny and counting personnel for voting on proposals shall be designated by the chairman, but the scrutiny personnel shall have the status of shareholders.

The counting of votes or election proposals at the shareholders' meeting shall be done in a public place at the shareholders' meeting, and after the counting of votes is completed, the voting results shall be announced on the spot, including the counting weights, and shall be recorded.

The company holds a video meeting of the shareholders meeting. Shareholders who participate in the video conference shall vote on various proposals and election proposals through the video conference platform after the chairman announces the opening of the meeting. deemed a waiver.

If the shareholders' meeting is convened by videoconference, after the chairman announces that the voting is over, the votes shall be counted at one time, and the voting and election results shall be announced.

When the company holds a video-assisted shareholders' meeting, shareholders who have registered to attend the shareholders' meeting via videoconference in accordance with the provisions of Article 6, and wish to attend the physical shareholders' meeting in person, shall cancel the registration in the same manner as the registration two days before the shareholders' meeting; Those who cancel after the deadline can only attend the shareholders' meeting via video conference.

Those who exercise voting rights in writing or electronically without revoking their declaration of intention and participate in the shareholders' meeting by videoconference shall not exercise voting rights on the original proposals, propose amendments to the original proposals, or exercise voting rights on amendments to the original proposals, except for ad hoc motions.

Article 14. When the shareholders' meeting elects directors, it shall follow the director election method stipulated by the company, and the election results shall be announced on the spot, including the list of elected directors, independent directors and their number of votes, and the list of unsuccessful directors and their voting rights. number.

The ballots for the elections mentioned in the preceding paragraph shall be sealed and signed by the scrutineers, and shall be kept in a safe place for at least one year. However, if a shareholder files a lawsuit in accordance with Article 189 of the Company Law, it shall be preserved until the lawsuit is concluded.

Article 15. The resolutions of the shareholders' meeting shall be recorded in minutes, signed or sealed by the chairman, and distributed to all shareholders within 20 days after the meeting. The production and distribution of the meeting minutes may be done electronically.

The distribution of the minutes of the proceedings mentioned in the preceding paragraph may be done by means of an announcement entered by the Public Information Observatory.

The minutes of the meeting shall be recorded according to the year, month, day, place, name of the chairman, resolution method, essentials of the proceedings and voting results (including statistical weights) of the meeting. When directors and independent directors are elected, each candidate shall be disclosed The number of votes a person has. During the existence of the company, it shall be permanently preserved.

The resolution method mentioned in the preceding paragraph is based on the chairman's consultation with shareholders. If shareholders have no objection to the proposal, it should record "passed after the chairman's consultation with all present shareholders without objection." proportional to weight.

If the shareholders meeting is convened by videoconference, in addition to the matters that shall be recorded in accordance with the provisions of the preceding paragraph, the minutes shall also record the start and end time of the shareholders meeting, the method of convening the meeting, the name of the chairman and the minutes, and records of events caused by natural disasters, accidents or other force majeure. The handling method and handling situation when there is an obstacle to the video conferencing platform or participation in the form of video.

The Company shall hold a video-conference shareholders meeting, in addition to following the provisions of the preceding paragraph, and shall state in the minutes of the meeting that there are alternative measures provided by shareholders who have difficulties participating in video-conferencing.

Article 16. For the number of shares acquired by the solicitor, the number of shares represented

by the entrusted agent, and the number of shares attended by shareholders in written or electronic form, the company shall prepare a statistical table in accordance with the prescribed format on the day of the shareholders' meeting. Clear announcements are made at the shareholders meeting; if the shareholders meeting is held by video conference, the company shall upload the above-mentioned information to the shareholders meeting video conference platform at least 30 minutes before the meeting, and continue to disclose it until the end of the meeting.

When the company holds a video conference of the shareholders' meeting and announces the meeting, the total number of shareholders' shares present shall be disclosed on the video conference platform. The same shall apply if the total number of shares and voting rights of shareholders present are counted separately during the meeting.

For resolutions of the shareholders' meeting, if there is any material information required by laws and regulations or by the OTC Securities Trading Center of the Republic of China, the company shall transmit the content to the public information observation station within the specified time.

Article 17. Personnel handling the shareholders' meeting shall wear identification cards or armbands.

The chairman may direct pickets or security personnel to assist in maintaining order at the venue. When pickets or security personnel are present to help maintain order, they should wear armbands or identification cards with the words "Pickets".

If the venue is equipped with sound amplification equipment, the chairman may stop the shareholders from speaking through the equipment provided by the company. Shareholders who violate the rules of procedure and refuse to obey the chairman's correction, obstruct the progress of the meeting and refuse to comply, may be ordered by the chairman to ask the pickets or security personnel to leave the meeting place.

Article 18. When the meeting is in progress, the chairman may announce a break at a discretionary time. When an irresistible event occurs, the chairman may rule to temporarily suspend the meeting and announce the time for the continuation of the meeting depending on the situation.

Before the conclusion of the agenda scheduled by the shareholders' meeting (including temporary motions), the venue for the meeting cannot continue to be used at that time, and the shareholders' meeting may resolve to find another venue to continue the meeting.

The shareholders' meeting may, in accordance with Article 182 of the Company Law, resolve to postpone or continue the meeting within five days.

Article 19. If the shareholders' meeting is held by video conference, the company shall immediately disclose the voting results of various proposals and election results on the video conference platform of the shareholders' meeting after the voting ends, and shall, after the chairman announces the adjournment of the meeting, continue to expose for at least fifteen minutes.

Article 20. When the company holds a video-conference shareholders meeting, the chairman and

recorder should be at the same place in China, and the chairman should announce the address of the place when the meeting is held.

Article 21. If the shareholders' meeting is held by video conference, the company may provide shareholders with a simple connection test before the meeting, and provide relevant services immediately before the meeting and during the meeting to assist in dealing with technical problems in communication.

If the shareholders' meeting is convened by videoconference, the chairman shall, when announcing the opening of the meeting, separately announce that there is no need to postpone or continue the meeting except for the circumstances specified in Item 24, Article 44 of the Standards for the Handling of Stock Affairs of Public Offering Companies. Before the adjournment of the meeting, due to natural disasters, accidents or other force majeure, if the video conferencing platform or participation in video conferencing is hindered and lasts for more than 30 minutes, the date of the meeting shall be postponed or continued within five days, and the company law does not apply. Article 182.

Shareholders who have not registered to participate in the original shareholders' meeting via video conference shall not participate in the postponed or continued meeting in the event of the occurrence of the preceding paragraph.

The meeting shall be postponed or resumed according to the provisions of Paragraph 2. Shareholders who have registered to participate in the original shareholders' meeting and completed the registration through video conference, and those who have not participated in the postponed or continued meeting, the number of shares attended at the original shareholders' meeting, the voting rights exercised and Voting rights shall be included in the total number of shares, voting rights and voting rights of shareholders present at the postponed or resumed meeting.

When adjourning or adjourning a general meeting of shareholders in accordance with the provisions of Paragraph 2, no re-discussion and resolution is required for proposals that have completed voting and counting, and announced the voting results or lists of directors and supervisors.

When the company convenes a video-assisted shareholders' meeting, and the video conference cannot be continued under Paragraph 2, if the total number of shares present after deducting the number of shares attending the shareholders' meeting by video-conference still reaches the statutory quota for the shareholders' meeting, the shareholders' meeting shall continue. There is no need to postpone or continue the meeting in accordance with the provisions of the second paragraph.

In the event that the meeting should continue as mentioned in the preceding paragraph, the shareholders who participate in the shareholders meeting via video conference shall count the number of shares present in the total number of shares of the shareholders present, but shall be deemed as abstaining from voting on all the resolutions of the shareholders meeting.

When the company postpones or continues the meeting in accordance with the provisions of the second paragraph, it shall follow the provisions listed in Article 44-

27 of the Standards for the Handling of Share Affairs of Public Offering Companies, and handle relevant matters in accordance with the original date of the shareholders' meeting and the provisions of each article. Preliminary work.

The second paragraph of Article 12 and Item 3 of Article 13 of the Rules for the Use of Power of Attorneys for Attending Shareholders' Meetings by Public Offering Companies, the Second Item of Article 44-5, and Article 44-10 of the Guidelines for the Handling of Stock Affairs of Public Offering Companies 5. During the period specified in Paragraph 1 of Article 44-17, the company shall postpone or continue the date of the shareholder meeting in accordance with the provisions of Paragraph 2.

Article 22. When the company holds a video-conference shareholders meeting, it shall provide appropriate alternative measures for shareholders who have difficulties in attending the shareholder meeting via video conference.

Except for the circumstances stipulated in Paragraph 6 of Article 44-9 of the Standards for Handling Stock Affairs of Companies with Public Issuance of Stocks, shareholders should at least be provided with connection equipment and necessary assistance, and the period during which shareholders can apply to the company and other relevant matters should be noted. matter.

Article 23. These rules shall be implemented after the resolution of the board of directors of the company and the approval of the shareholders' meeting. The same is true for amendments.

Article 24. These rules were enacted on June 25, 2008.

First revised edition: November 01, 2008.

The second revision: June 29, 2012.

The third revision: June 20, 2013.

The fourth revision: June 23, 2015.

The fifth revised edition: June 27, 2018.

Sixth revision: June 30, 2020.

The seventh revised edition: July 30, 2021.

The eighth revision: June 29, 2022.

The ninth revised: June 30, 2023.

Appendix 3: Shareholding of Directors

- (1) The shareholding status of all directors recorded in the shareholder register as of the closing date of the shareholders meeting (2025.4.18) is as follows:

Title	Name	Closing Date	
		Shares	Ratio
Chairman	MISSIONCARE CO. Representative: Yang Hongren	39,637,732	28.80%
Director	MISSIONCARE CO. Representative: Xu Shengxin		
Director	MISSIONCARE CO. Representative: Liu Qingwen		
Director	MISSIONCARE CO. Representative: Sun Zhili		
Director	MISSIONCARE CO. Representative: Chen Wenzhong		
Director	Rongyang Management Consulting Co., Ltd. Representative: Zhang Changrong	146,249	0.11%
Director	Yang Chen Caibi	1,547,113	1.12%
Independent Director	Wu Geunzai	0	0.00%
Independent Director	Li Shuxing	0	0.00%
Independent Director	Chen Houming	0	0.00%
Independent Director	Yao Xiubi	0	0.00%
Total Amount		41,331,094	30.03%

- (2) The company's paid-in capital is 1,376,403,430 yuan, and the number of issued shares is 137,640,343 shares. According to the "Public Issuance of Directors, Supervisors' Shareholding Ratio and Inspection Implementation Rules", the legal minimum number of shares held by all Directors is 8,000,000 shares.
- (3) The company has an audit committee, so there is no statutory number of shares held by supervisors.

ShareHope


SHAREHOPE MEDICINE CO., LTD.


Stock Code: 8403

115

Annual Shareholders' Meeting Handbook

 Meeting Time: 9:00 AM, June 23, 2026

 Venue: 5F., No. 107, Minsheng Rd.,
Taoyuan Dist., Taoyuan City

 Meeting Format: In-Person
Shareholders' Meeting



Missioncare / Since 1975

Missioncare HealthCare

Asia's Leading Healthcare Ecosystem



50+

Years of Heritage



18

Cities & Counties
Served



1,233

Service Locations
Nationwide



Missioncare Website

<https://www.missioncareasia.com/>